var title_f34_9_34960="Scopolamine: Pediatric drug information";
var content_f34_9_34960=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Scopolamine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12645383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/56/9092?source=see_link\">",
"       Scopolamine (ophthalmic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/0/39941?source=see_link\">",
"       Scopolamine (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12782 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-D60132E406-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_9_34960=[""].join("\n");
var outline_f34_9_34960=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/56/9092?source=related_link\">",
"      Scopolamine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/0/39941?source=related_link\">",
"      Scopolamine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_9_34961="Hairy leukoplakia in HIV";
var content_f34_9_34961=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hairy leukoplakia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Well-demarcated white plaques are visible on the lateral aspects of the tongue, which cleared with oral acyclovir.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Williams and Wilkins, Baltimore 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_9_34961=[""].join("\n");
var outline_f34_9_34961=null;
var title_f34_9_34962="Incontinentia pigmenti 4";
var content_f34_9_34962=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Incontinentia pigmenti",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    \"Marble cake\" hyperpigmentation in a female infant with incontinentia pigmenti.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_9_34962=[""].join("\n");
var outline_f34_9_34962=null;
var title_f34_9_34963="CT cystogram bladder rupture coronal";
var content_f34_9_34963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT cystogram of bladder rupture - Coronal view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This coronal view of a CT cystogram shows extravasated contrast encircling the bladder.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael S Runyon, MD, FAAEM.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_9_34963=[""].join("\n");
var outline_f34_9_34963=null;
var title_f34_9_34964="Map of states with recalled methylprednisolone";
var content_f34_9_34964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 634px\">",
"   <div class=\"ttl\">",
"    Map of healthcare facilities that received lots* of methylprednisolone acetate (PF) recalled from New England Compounding Center on September 26, 2012",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 614px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PF: preservative-free.",
"     <br/>",
"     * Lot #05212012@68, BUD 11/17/2012; Lot #06292012@26, BUD 12/26/2012; Lot #08102012@51, BUD 2/6/2013.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     All vials of methylprednisolone acetate that were sent to Nevada were recalled prior to use.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Healthcare-associated Infections (HAIs): Map of Healthcare Facilities which Received Three Lots of Methylprednisolone Acetate (PF) Recalled from New England Compounding Center on September 26, 2012. Available at:",
"     <a href=\"file://www.cdc.gov/hai/outbreaks/meningitis-facilities-map.html\" target=\"_blank\">",
"      file://www.cdc.gov/hai/outbreaks/meningitis-facilities-map.html",
"     </a>",
"     (Accessed October 11, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_9_34964=[""].join("\n");
var outline_f34_9_34964=null;
var title_f34_9_34965="Postoperative management of adults with obstructive sleep apnea";
var content_f34_9_34965=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Postoperative management of adults with obstructive sleep apnea",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/9/34965/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/9/34965/contributors\">",
"     Eric Olson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/9/34965/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/9/34965/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/9/34965/contributors\">",
"     Stephanie B Jones, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/9/34965/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/9/34965/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/9/34965/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2526365\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive sleep apnea (OSA) is a disorder characterized by repetitive episodes of apnea or reduced inspiratory airflow due to upper airway obstruction during sleep. The incidence of perioperative complications (ie, preoperative, intraoperative, and postoperative complications collectively) is increased among patients with OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34965/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The Joint Commission has suggested that a National Patient Safety Goal be the reduction of perioperative complications among patients with OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34965/abstract/4\">",
"     4",
"    </a>",
"    ], while the American Society of Anesthesiology (ASA) and American Academy of Sleep Medicine (AASM) have developed clinical practice guidelines for the perioperative management of patients with OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34965/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Common among the guidelines is an emphasis on maintaining a high index of suspicion for OSA, careful use of medications, vigilant monitoring for evidence of upper airway obstruction, an integrated team approach to perioperative management, and recognition that many recommendations are based upon clinical rationale and indirect evidence because direct evidence is scarce. Such interest in the perioperative management of patients with OSA probably reflects the recognition that the number of patients with OSA encountered in operating rooms is likely to increase as recognition of the disease and the prevalence of obesity increase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34965/abstract/5,8\">",
"     5,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The early postoperative period can be especially tenuous for patients with OSA, as suggested by a case-control study that found that most cardiorespiratory complications occurred during the first postoperative day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34965/abstract/9\">",
"     9",
"    </a>",
"    ]. This is likely because numerous factors that can exacerbate OSA (eg, opioid analgesia) are active during this time (",
"    <a class=\"graphic graphic_table graphicRef71284 \" href=\"mobipreview.htm?5/53/5979\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The postoperative management of patients with OSA is reviewed here. Factors that contribute to the increased surgical risk of patients with OSA, preoperative evaluation, preoperative management, and intraoperative management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35288?source=see_link\">",
"     \"Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/0/37893?source=see_link\">",
"     \"Intraoperative management of adults with obstructive sleep apnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2526372\">",
"    <span class=\"h1\">",
"     PAIN CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioid analgesics inhibit the upper respiratory muscles and, therefore, they have the potential to induce or worsen upper airway collapse. It seems desirable to avoid or minimize the postoperative use of opioids in patients with OSA (since these patients are predisposed to upper airway collapse), even though this strategy has not consistently reduced postoperative complications in surgical patients without OSA and has not been studied specifically in patients with OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34965/abstract/10\">",
"     10",
"    </a>",
"    ]. This is particularly true among patients with more severe OSA.",
"   </p>",
"   <p>",
"    The use of regional analgesia (eg, peripheral nerve blocks)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    non-opioid analgesics (eg, nonsteroidal antiinflammatory drugs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ) are strategies that may reduce or eliminate the need for systemic opioids postoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34965/abstract/7\">",
"     7",
"    </a>",
"    ]. Neuraxial analgesia (eg, spinal analgesia, epidural analgesia) may also reduce the need for postoperative systemic opioids. However, neuraxial analgesia must be employed with caution because it can be complicated by respiratory depression and sedation if the drug extends too far cephalad [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34965/abstract/11\">",
"     11",
"    </a>",
"    ]. The risk of such complications may be decreased by using local anesthetics without the addition of opioids for neuraxial analgesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34965/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether patient-controlled analgesia reduces OSA-related postoperative complications relative to nurse administered pain medication is uncertain and controversial. It is also unclear whether a basal opioid infusion is harmful, but most organizations suggest avoiding such infusions in patients with OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34965/abstract/7\">",
"     7",
"    </a>",
"    ]. Concurrent prescription of sedatives (eg, anxiolytics) should also be avoided or minimized in patients with OSA who are receiving systemic opioids because sedatives can act synergistically with opioids to decrease central respiratory drive and inhibit upper airway muscles, leading to upper airway collapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2526379\">",
"    <span class=\"h1\">",
"     OXYGENATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with OSA typically receive supplemental oxygen postoperatively until they are able to maintain their baseline oxyhemoglobin saturation while breathing room air [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34965/abstract/7\">",
"     7",
"    </a>",
"    ]. The goal is an oxyhemoglobin saturation level greater than or equal to 90 percent, both while awake and during sleep.",
"   </p>",
"   <p>",
"    There is no evidence that routine postoperative supplemental oxygen improves clinical outcomes. Thus, the use of supplemental oxygen is based upon the observations that patients with OSA can quickly desaturate during the postoperative period and that hypoxemia may have serious adverse consequences. The desirable effects of preventing hypoxemia seem to outweigh the potential for supplemental oxygen to prolong or mask apneas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2526386\">",
"    <span class=\"h1\">",
"     OSA-SPECIFIC THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most postoperative patients with confirmed or presumed OSA will have begun positive airway pressure or an oral appliance prior to surgery. This was discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35288?source=see_link&amp;anchor=H15227571#H15227571\">",
"     \"Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea\", section on 'Preoperative management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Such patients should resume their positive airway pressure therapy or oral appliance therapy during sleep as soon as feasible after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34965/abstract/7\">",
"     7",
"    </a>",
"    ]. This requires that nurses and respiratory therapists be available and trained to assist patients with placement of their positive airway pressure (usually continuous positive airway pressure [CPAP]), as well as to troubleshoot interface problems (eg, offer a full-face mask if there is either nasal packing or a nasogastric tube in place), observe for breakthrough upper airway obstruction, and reassure patients.",
"   </p>",
"   <p>",
"    Positive airway pressure therapy should be initiated at the level prescribed preoperatively. If this is not known, it is reasonable to begin at an empiric level of 8 to 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O and then titrate the level until apneas, episodes of oxyhemoglobin desaturation, and snoring are eliminated. Auto-titrating CPAP devices are also a reasonable option. Supplemental oxygen can be added to any positive airway pressure device via a port on the mask or a port on the tubing that connects the blower unit to the patient.",
"   </p>",
"   <p>",
"    For the less common patient with confirmed OSA in whom therapy is indicated but was never begun preoperatively, it is reasonable to try to initiate positive airway pressure therapy using the same approach described above. However, this may be difficult because postoperative patients who are na&iuml;ve or previously intolerant of positive airway pressure therapy are less likely to tolerate a new therapy in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34965/abstract/12\">",
"     12",
"    </a>",
"    ]. Clinical experience suggests that adding heated humidification and a pressure ramp may help acutely with adherence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10296?source=see_link\">",
"     \"Initiation of positive airway pressure therapy for obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a paucity of evidence addressing the impact of early postoperative therapy for OSA on postoperative outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34965/abstract/7\">",
"     7",
"    </a>",
"    ]. However, there is moderate to high quality evidence from non-surgical patients that the treatment of OSA improves physiological outcomes that may be risk factors for perioperative complications (eg, blood pressure). This is the rationale for initiating OSA therapy postoperatively.",
"   </p>",
"   <p>",
"    Positive airway pressure therapy is NOT contraindicated after upper gastrointestinal surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34965/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2526393\">",
"    <span class=\"h1\">",
"     POSITIONING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The supine position worsens OSA in some patients. Thus, it seems reasonable to care for postoperative patients who have OSA in the lateral or upright position, if possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34965/abstract/7\">",
"     7",
"    </a>",
"    ]. A reasonable endpoint for care in this position is when the need for opioid analgesics and sedatives is minimal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of obstructive sleep apnea in adults\", section on 'Sleep position'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefit of caring for postoperative patients with OSA in a non-supine position compared to a supine position has never been studied. The suggestion to use the lateral position postoperatively is based upon observational evidence from nonsurgical patients with OSA that indicates that sleeping in a non-supine position improves the apnea hypopnea index and oxyhemoglobin saturation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34965/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2526400\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with OSA who are undergoing inpatient surgery should be monitored with continuous pulse oximetry after discharge from the recovery room if they are at increased risk for postoperative complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34965/abstract/7\">",
"     7",
"    </a>",
"    ]. Several scoring systems exist to help clinicians identify patients who are at increased risk for postoperative complications, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A scoring system developed by the American Society of Anesthesiologists (ASA) to assess the risk of perioperative complications (ie, preoperative, intraoperative, and postoperative complications collectively) in patients with OSA may be helpful in identifying patients who should be monitored with continuous pulse oximetry, although its use for this purpose has not been validated (",
"      <a class=\"graphic graphic_table graphicRef70982 \" href=\"mobipreview.htm?21/41/22173\">",
"       table 2",
"      </a>",
"      ). The scoring system has three components: the severity of the OSA (based upon a sleep study or clinical indicators), the invasiveness of the surgery and type of anesthesia planned, and the anticipated need for postoperative opioid analgesia. These components are used to calculate a score between zero and six. Patients with a score of four or more are considered to be at increased risk for postoperative complications and should be monitored with continuous pulse oximetry after discharge from the recovery room [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34965/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Flemons&rsquo; screening tool is routinely used to screen preoperative patients for OSA, but it can also be applied postoperatively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34965/abstract/15\">",
"       15",
"      </a>",
"      ]. Data on neck circumference, hypertension, and clinical symptoms are incorporated into the model to derive a sleep apnea clinical score (SACS). A high SACS combined with an increased frequency of respiratory events (ie, apnea, bradypnea, desaturations, and pain-sedation mismatch) in the post-anesthesia recovery unit predicts an increased risk for subsequent post-operative oxygen desaturation events and respiratory complications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34965/abstract/16\">",
"       16",
"      </a>",
"      ]. &nbsp; &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Continuous pulse oximetry may be monitored at the bedside in a critical care or stepdown unit, by telemetry on a hospital ward, or by a dedicated and trained observer in the patient&rsquo;s room. The optimal method must be selected on a case-by-case basis after considering the severity of the OSA, type of operation performed, opioid and sedative requirements, and available resources. Continuous pulse oximetry should continue until they are no longer at increased risk. There are no universally accepted criteria available to define when a patient is no longer at increased risk. However, reasonable considerations include the discontinuation of opioid analgesics and sedatives, ad lib sleep positioning (ie, the patient is no longer confined to the supine position during sleep), adequate oxygenation (ie, an oxyhemoglobin saturation &gt;90 to 92 percent on room air or oxygenation mirroring the patient&rsquo;s baselines status), maintenance of clear mental status, and satisfactory resumption of positive airway pressure therapy or oral appliance therapy during sleep.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5934032\">",
"    <span class=\"h1\">",
"     DISCHARGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with OSA who are undergoing outpatient surgery should not be discharged until they can maintain a patent airway without being stimulated and their oxyhemoglobin saturation is maintained at baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34965/abstract/7\">",
"     7",
"    </a>",
"    ]. Generally speaking, it is preferable to monitor patients with OSA a median of 3 hours longer than patients without OSA prior to discharge. The same criteria apply to patients with OSA who are undergoing inpatient surgery, although these issues generally resolve before the patient is ready for discharge from a surgical standpoint. For those patients treated presumptively for OSA, discharge planning should include follow-up with a sleep specialist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2526407\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstructive sleep apnea (OSA) is a disorder characterized by repetitive episodes of apnea or reduced inspiratory airflow due to upper airway obstruction during sleep. The incidence of perioperative complications is increased among patients with OSA. (See",
"      <a class=\"local\" href=\"#H2526365\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postoperative aspects of managing patients with OSA are discussed in this review. Factors that contribute to the increased surgical risk of patients with OSA, preoperative evaluation, preoperative management, and intraoperative management are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35288?source=see_link\">",
"       \"Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/0/37893?source=see_link\">",
"       \"Intraoperative management of adults with obstructive sleep apnea\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that postoperative patients with OSA be managed using an analgesic strategy that minimizes the need for systemic opioids (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Such strategies include regional analgesia, nonsteroidal antiinflammatory drugs, or neuraxial analgesia without opioids. (See",
"      <a class=\"local\" href=\"#H2526372\">",
"       'Pain control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All postoperative patients with OSA typically receive supplemental oxygen after surgery. This should be continued until they are able to maintain their baseline oxyhemoglobin saturation while breathing room air. (See",
"      <a class=\"local\" href=\"#H2526379\">",
"       'Oxygenation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that postoperative patients with OSA who were receiving therapy prior to surgery resume the therapy as soon as feasible after surgery, rather than delaying until after discharge (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Postoperative patients with OSA who were not receiving therapy prior to surgery may also benefit from a trial of therapy. (See",
"      <a class=\"local\" href=\"#H2526386\">",
"       'OSA-specific therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that postoperative patients with OSA be cared for in the lateral position, rather than the supine position (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      We suggest that postoperative patients with OSA be monitored with continuous pulse oximetry after discharge from the recovery room, rather than intermittent pulse oximetry (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A scoring system developed by the American Society of Anesthesiologists (ASA) to assess the risk of perioperative complications in patients with OSA may be helpful in identifying patients at increased risk for postoperative complications (",
"      <a class=\"graphic graphic_table graphicRef70982 \" href=\"mobipreview.htm?21/41/22173\">",
"       table 2",
"      </a>",
"      ); patients with a score of four or more or those with an increased frequency of respiratory events (ie, apnea, bradypnea, desaturations) in the post-anesthesia recovery unit should be monitored with continuous pulse oximetry. (See",
"      <a class=\"local\" href=\"#H2526400\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34965/abstract/1\">",
"      Hillman DR, Loadsman JA, Platt PR, Eastwood PR. Obstructive sleep apnoea and anaesthesia. Sleep Med Rev 2004; 8:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34965/abstract/2\">",
"      Boushra NN. Anaesthetic management of patients with sleep apnoea syndrome. Can J Anaesth 1996; 43:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34965/abstract/3\">",
"      Chung SA, Yuan H, Chung F. A systemic review of obstructive sleep apnea and its implications for anesthesiologists. Anesth Analg 2008; 107:1543.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.hcpro.com/NRS-66500-975/Sleep-apnea-among-proposed-National-Patient-Safety-Goals.html (Accessed on June 10, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34965/abstract/5\">",
"      Benumof JL. Obstructive sleep apnea in the adult obese patient: implications for airway management. Anesthesiol Clin North America 2002; 20:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34965/abstract/6\">",
"      Meoli AL, Rosen CL, Kristo D, et al. Upper airway management of the adult patient with obstructive sleep apnea in the perioperative period--avoiding complications. Sleep 2003; 26:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34965/abstract/7\">",
"      Gross JB, Bachenberg KL, Benumof JL, et al. Practice guidelines for the perioperative management of patients with obstructive sleep apnea: a report by the American Society of Anesthesiologists Task Force on Perioperative Management of patients with obstructive sleep apnea. Anesthesiology 2006; 104:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34965/abstract/8\">",
"      Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34965/abstract/9\">",
"      Gupta RM, Parvizi J, Hanssen AD, Gay PC. Postoperative complications in patients with obstructive sleep apnea syndrome undergoing hip or knee replacement: a case-control study. Mayo Clin Proc 2001; 76:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34965/abstract/10\">",
"      Liu SS, Wu CL. Effect of postoperative analgesia on major postoperative complications: a systematic update of the evidence. Anesth Analg 2007; 104:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34965/abstract/11\">",
"      Lamarche Y, Martin R, Reiher J, Blaise G. The sleep apnoea syndrome and epidural morphine. Can Anaesth Soc J 1986; 33:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34965/abstract/12\">",
"      Rennotte MT, Baele P, Aubert G, Rodenstein DO. Nasal continuous positive airway pressure in the perioperative management of patients with obstructive sleep apnea submitted to surgery. Chest 1995; 107:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34965/abstract/13\">",
"      Huerta S, DeShields S, Shpiner R, et al. Safety and efficacy of postoperative continuous positive airway pressure to prevent pulmonary complications after Roux-en-Y gastric bypass. J Gastrointest Surg 2002; 6:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34965/abstract/14\">",
"      Jokic R, Klimaszewski A, Crossley M, et al. Positional treatment vs continuous positive airway pressure in patients with positional obstructive sleep apnea syndrome. Chest 1999; 115:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34965/abstract/15\">",
"      Flemons WW, Whitelaw WA, Brant R, Remmers JE. Likelihood ratios for a sleep apnea clinical prediction rule. Am J Respir Crit Care Med 1994; 150:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34965/abstract/16\">",
"      Gali B, Whalen FX, Schroeder DR, et al. Identification of patients at risk for postoperative respiratory complications using a preoperative obstructive sleep apnea screening tool and postanesthesia care assessment. Anesthesiology 2009; 110:869.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13518 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-AB43D6AFE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_9_34965=[""].join("\n");
var outline_f34_9_34965=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2526407\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2526365\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2526372\">",
"      PAIN CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2526379\">",
"      OXYGENATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2526386\">",
"      OSA-SPECIFIC THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2526393\">",
"      POSITIONING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2526400\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5934032\">",
"      DISCHARGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2526407\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/13518\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/13518|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/53/5979\" title=\"table 1\">",
"      Periop factors aggravating OSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/41/22173\" title=\"table 2\">",
"      OSA scoring system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10296?source=related_link\">",
"      Initiation of positive airway pressure therapy for obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/0/37893?source=related_link\">",
"      Intraoperative management of adults with obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35288?source=related_link\">",
"      Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_9_34966="Plasmodium blood smears";
var content_f34_9_34966=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Red blood cell morphology in various forms of Plasmodium infections",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 511px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Identification of a schizont with &gt;12 merozoites in the peripheral circulation is an important diagnostic clue for P. vivax. In general, schizonts of P. falciparum are very rarely seen in blood films; they are generally absent from the peripheral circulation except in cases of severe infection with overwhelming parasitemia.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_9_34966=[""].join("\n");
var outline_f34_9_34966=null;
var title_f34_9_34967="Beta chain variants reverse HPLC";
var content_f34_9_34967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 575px\">",
"   <div class=\"ttl\">",
"    Beta chain variants reverse HPLC",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 555px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Reversed phase HPLC separation of variant beta-globin chains. Normal beta and alpha chains are highlighted. The separation of hemoglobins into their component globin chains and heme, which is eluted earlier, is achieved by the chemical composition of the buffer used in this technique, namely 0.1 M trifluoroacetic acid (TFA) and acetonitrile.",
"    <div class=\"footnotes\">",
"     HPLC: high performance liquid chromatography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_9_34967=[""].join("\n");
var outline_f34_9_34967=null;
var title_f34_9_34968="Hematopoiesis regulation";
var content_f34_9_34968=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F52024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F52024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 626px\">",
"   <div class=\"ttl\">",
"    Regulation of hematopoiesis via growth factors and cytokines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 606px; height: 786px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure illustrates the hierarchical relationships of pluripotent hematopoietic stem cells (PHSC), progenitors, and mature cells of the myelopoietic, erythrocyte, and platelet lineages together with major growth factors, cytokines, and their actions. The involved growth factors and cytokines have overlapping actions during hematopoietic differentiation, as indicated, and, for most lineages, optimal development requires a combination of early- and late-acting factors. Please see text for an explanation of the various abbreviations used in this figure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Sieff, CA, Zon, LI. Anatomy and Physiology of Hematopoiesis. In: Nathan and Oski's Hematology of Infancy and Childhood, 7th ed, Orkin, S, Fisher, D, Look, AT, et al. (Eds) Elsevier, Philadelphia 2009. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_9_34968=[""].join("\n");
var outline_f34_9_34968=null;
var title_f34_9_34969="Clopidogrel: Drug information";
var content_f34_9_34969=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clopidogrel: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/11/21685?source=see_link\">",
"    see \"Clopidogrel: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/49/16152?source=see_link\">",
"    see \"Clopidogrel: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F10072956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F153626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Plavix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F153627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Clopidogrel&reg;;",
"     </li>",
"     <li>",
"      CO Clopidogrel;",
"     </li>",
"     <li>",
"      Dom-Clopidogrel;",
"     </li>",
"     <li>",
"      Mylan-Clopidogrel;",
"     </li>",
"     <li>",
"      Plavix&reg;;",
"     </li>",
"     <li>",
"      PMS-Clopidogrel;",
"     </li>",
"     <li>",
"      RAN&trade;-Clopidogrel;",
"     </li>",
"     <li>",
"      Sandoz-Clopidogrel;",
"     </li>",
"     <li>",
"      Teva-Clopidogrel",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F153658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiplatelet Agent;",
"     </li>",
"     <li>",
"      Antiplatelet Agent, Thienopyridine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F153630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Recent MI, recent stroke, or established peripheral arterial disease (PAD):",
"     </b>",
"     Oral: 75 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     The ACCF/AHA guidelines for PAD recommend clopidogrel as an alternative to aspirin (Class Ib recommendation) or in conjunction with aspirin for those who are not at an increased risk of bleeding but are of high cardiovascular risk (Class IIb recommendation). These recommendations also pertain to those with intermittent claudication or critical limb ischemia, prior lower extremity revascularization, or prior amputation for lower extremity ischemia (Rooke, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Coronary artery disease (CAD), established:",
"     </b>",
"     Oral: 75 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Established CAD defined as patients 1-year post ACS, with prior revascularization, coronary stenosis &gt;50% by angiogram, and/or evidence for cardiac ischemia on diagnostic testing (includes patients after the first year post-ACS and/or with prior CABG surgery) (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Secondary prevention of cardioembolic stroke (patient not candidate for oral anticoagulation):",
"     </b>",
"     Oral: 75 mg once daily (in combination with aspirin) (Guyatt, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute coronary syndrome (ACS):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Unstable angina, non-ST-segment elevation myocardial infarction (UA/NSTEMI):",
"     </i>",
"     Initial: 300 mg loading dose, followed by 75 mg once daily for up to 12 months (in combination with aspirin indefinitely) (Jneid, 2012). The American College of Chest Physicians recommends combination aspirin dose of 75-100 mg (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      ST-segment elevation myocardial infarction (STEMI):",
"     </i>",
"     75 mg once daily (in combination with aspirin 162-325 mg initially followed by 81-162 mg/day",
"     <b>",
"      or",
"     </b>",
"     75-100 mg/day [Guyatt, 2012]).",
"     <b>",
"      Note:",
"     </b>",
"     CLARITY-TIMI 28 used a 300 mg loading dose (with thrombolysis) demonstrating an improvement in the patency rate of the infarct related artery and reduction in ischemic complications. The duration of therapy was &lt;28 days (usually until hospital discharge) unless nonprimary percutaneous coronary intervention (PCI) was performed (Sabatine, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Percutaneous coronary intervention (PCI) for acute coronary syndrome (eg, UA/NSTEMI or STEMI):",
"     </i>",
"     Loading dose: 600 mg given as early as possible before or at the time of PCI, followed by 75 mg once daily (in combination with aspirin 81 mg/day).",
"     <b>",
"      Note:",
"     </b>",
"     If fibrinolytic administered within the previous 24 hours, administer 300 mg loading dose instead (Levine, 2011). The use of ticagrelor (instead of clopidogrel) in combination with aspirin has been suggested (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Higher versus standard maintenance dosing: May consider a maintenance dose of 150 mg once daily for 6 days, then 75 mg once daily thereafter in patients not at high risk for bleeding (CURRENT-OASIS 7 Investigators, 2010; Jneid, 2012); however, in another study, in patients with high on-treatment platelet reactivity, the use of 150 mg once daily for 6 months did not demonstrate a difference in 6-month incidence of death from cardiovascular causes, nonfatal MI, or stent thrombosis compared to standard dose therapy (Price, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Duration of clopidogrel (in combination with aspirin) after stent placement for ACS and non-ACS indications:",
"     <b>",
"      Premature interruption of therapy may result in stent thrombosis with subsequent fatal and nonfatal MI.",
"     </b>",
"     At least 12 months of clopidogrel is recommended for those with ACS receiving either stent type (bare metal [BMS] or drug eluting stent [DES]) or those receiving a DES for a non-ACS indication (ie, elective PCI). Those receiving a BMS for a non-ACS indication should be given at least 1 month and ideally up to 12 months; if patient is at increased risk of bleeding, give for a minimum of 2 weeks. A duration &gt;12 months, regardless of indication, may be considered in patients with DES placement (Jneid, 2012; Levine, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CYP2C19 poor metabolizers (ie,",
"     <i>",
"      CYP2C19*2",
"     </i>",
"     or",
"     <i>",
"      *3",
"     </i>",
"     carriers): Although routine genetic testing is not recommended in patients treated with clopidogrel undergoing PCI, testing may be considered to identify poor metabolizers who would be at risk for poor outcomes while receiving clopidogrel; if identified, these patients may be considered for an alternative P2Y",
"     <sub>",
"      12",
"     </sub>",
"     inhibitor (Levine, 2011). An appropriate regimen for this patient population has not been established in clinical outcome trials. Although the manufacturer suggests a 600 mg loading dose, followed by 150 mg once daily, it does not appear that this dosing strategy improves outcomes for this patient population (Price, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Atrial fibrillation (in patients not candidates for warfarin and at a low risk of bleeding) (Canadian labeling; ACTIVE Investigators, 2009; unlabeled use in U.S.):",
"     </b>",
"     Oral: 75 mg once daily (in combination with aspirin 75-100 mg once daily).",
"     <b>",
"      Note:",
"     </b>",
"     Combination may also be used as an alternative for patients with atrial fibrillation and mitral stenosis (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Carotid artery stenosis, symptomatic (including recent carotid endarterectomy) (unlabeled use):",
"     </b>",
"     Oral: 75 mg once daily (Guyatt, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Peripheral artery percutaneous transluminal angioplasty (with or without stenting) or peripheral artery bypass graft surgery, postprocedure (unlabeled use):",
"     </b>",
"     Oral: 75 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     For below-knee bypass graft surgery with prosthetic grafts, combine with aspirin 75-100 mg/day (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of coronary artery bypass graft closure (saphenous vein) and postoperative adverse cardiovascular events (unlabeled use):",
"     </b>",
"     Oral: Aspirin-allergic patients: 75 mg once daily (Hillis, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F153631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F153632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment is necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F153633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; experience is limited.",
"     <b>",
"      Note:",
"     </b>",
"     Inhibition of ADP-induced platelet aggregation and mean bleeding time prolongation were similar in patients with severe hepatic impairment compared to healthy subjects after repeated doses of 75 mg once daily for 10 days.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F153606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 75 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plavix&reg;: 75 mg, 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F153591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F11566548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM243349.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM243349.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9480379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F153608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduces rate of atherothrombotic events (myocardial infarction, stroke, vascular deaths) in patients with recent MI or stroke, or established peripheral arterial disease; reduces rate of atherothrombotic events in patients with unstable angina (UA) or non-ST-segment elevation MI (NSTEMI) managed medically or with percutaneous coronary intervention (PCI) (with or without stent) or CABG; reduces rate of death and atherothrombotic events in patients with ST-segment elevation MI (STEMI) managed medically",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional use (not in U.S. labeling): Prevention of atherothrombotic and thromboembolic events, including stroke, in patients with atrial fibrillation with at least 1 risk factor for vascular events who are not suitable for treatment with an anticoagulant and are at a low risk for bleeding.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F153654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In patients with allergy or major gastrointestinal intolerance to aspirin, initial treatment of acute coronary syndromes (ACS) or prevention of coronary artery bypass graft closure (saphenous vein); stable coronary artery disease (in combination with aspirin); in patients having undergone peripheral artery percutaneous transluminal angioplasty; symptomatic carotid artery stenosis (including recent carotid endarterectomy)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F153666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Plavix&reg; may be confused with Elavil&reg;, Paxil&reg;, Pradax&trade; (Canada), Pradaxa&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F153656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As with all drugs which may affect hemostasis, bleeding is associated with clopidogrel. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the concurrent use of multiple agents which alter hemostasis and patient susceptibility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     3% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (4%), pruritus (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Bleeding (major 4%; minor 5%), purpura/bruising (5%), epistaxis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 3%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: GI hemorrhage (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hematoma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute liver failure, agranulocytosis, anaphylactoid reaction, angioedema, aplastic anemia, arthralgia, arthritis, bronchospasm, bullous eruption, colitis (including ulcerative or lymphocytic), confusion, creatinine increased, eczema, erythema multiforme, fever, glomerulopathy, hallucination, hemorrhagic stroke (&le;0.2%), hepatitis, hypersensitivity reaction, hypotension, interstitial pneumonitis, intracranial hemorrhage (&le;0.4%), lichen planus, liver function tests (abnormal), musculoskeletal bleeding, myalgia, ocular bleeding (including conjunctival and retinal), pancreatitis, pancytopenia, pulmonary hemorrhage, rash (erythematous or maculopapular), retroperitoneal hemorrhage, serum sickness, Stevens-Johnson syndrome, stomatitis, taste disorder, thrombotic thrombocytopenic purpura (TTP), toxic epidermal necrolysis, vasculitis, wound hemorrhage",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F153611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clopidogrel or any component of the formulation; active pathological bleeding such as peptic ulcer or intracranial hemorrhage",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Significant liver impairment or cholestatic jaundice",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F153595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding: Clopidogrel increases the risk of bleeding. Use is contraindicated in patients with active pathological bleeding or intracranial hemorrhage. Additional risk factors for bleeding include age &ge;75 years, propensity to bleed (eg, recent trauma or surgery, recent or recurrent GI bleeding, active PUD, severe hepatic impairment), body weight &lt;60 kg, CABG or other surgical procedure, concomitant use of medications that increase risk of bleeding (eg, warfarin, NSAIDs). Bleeding should be suspected if patient becomes hypotensive after undergoing recent coronary angiography, PCI, CABG, or other surgical procedure even if overt signs of bleeding do not exist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thienopyridine hypersensitivity: Because of structural similarities, cross-reactivity is possible among the thienopyridines (clopidogrel, prasugrel, and ticlopidine); use with caution or avoid in patients with previous thienopyridine hypersensitivity. Use of clopidogrel is contraindicated in patients with hypersensitivity to clopidogrel, although desensitization may be considered for mild-to-moderate hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombotic thrombocytopenic purpura (TTP): Cases of TTP (usually occurring within the first 2 weeks of therapy), resulting in some fatalities, have been reported; urgent plasmapheresis is required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Atrial fibrillation: Approved indication in Canadian labeling (not in U.S. labeling): Assess bleeding risk carefully prior to initiating therapy in patients with atrial fibrillation; in clinical trials, a significant increase in major bleeding events (including intracranial hemorrhage and fatal bleeding events) were observed in patients receiving clopidogrel plus aspirin versus aspirin alone. Vitamin K antagonist (VKA) therapy (in suitable patients) has demonstrated a greater benefit in stroke reduction than aspirin (with or without clopidogrel).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with platelet disorders, bleeding disorders and/or at increased risk for bleeding (eg, PUD, trauma, or surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment (experience is limited). Use in patients with severe hepatic impairment or cholestatic jaundice is contraindicated in the Canadian labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lacunar stroke: In patients with recent lacunar stroke (within 180 days), the use of clopidogrel in addition to aspirin did not significantly reduce the incidence of the primary outcome of stroke recurrence (any ischemic stroke or intracranial hemorrhage) compared to aspirin alone; the use of clopidogrel in addition to aspirin did however increase the risk of major hemorrhage and the rate of all-cause mortality (SPS3 Investigators, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment (experience is limited).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticoagulants and platelet aggregation inhibitors: Use with caution in patients receiving either anticoagulants (eg, heparin, warfarin) or other platelet aggregation inhibitors; bleeding risk is increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aspirin: Concurrent use of aspirin and clopidogrel is not recommended for secondary prevention of ischemic stroke or TIA in patients unable to take oral anticoagulants due to hemorrhagic risk (Furie, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP2C19 inhibitors: Concurrent use with drugs known to inhibit CYP2C19 (eg, proton pump inhibitors) may reduce levels of active metabolite and subsequently reduce clinical efficacy and increase the risk of cardiovascular events; if possible, avoid concurrent use of moderate-to-strong CYP2C19 inhibitors. In patients requiring antacid therapy, consider use of an acid-reducing agent lacking (eg, ranitidine/famotidine) or with less CYP2C19 inhibition. According to the manufacturer, avoid concurrent use of omeprazole (even when scheduled 12 hours apart) or esomeprazole; if a PPI is necessary, the use of an agent with comparatively less effect on the antiplatelet activity of clopidogrel is recommended. Of the PPIs, pantoprazole has the lowest degree of CYP2C19 inhibition",
"     <i>",
"      in vitro",
"     </i>",
"     (Li, 2004) and has been shown to have has less effect on conversion of clopidogrel to its active metabolite compared to omeprazole (Angiolillo, 2011). Although lansoprazole exhibits the most potent CYP2C19 inhibition",
"     <i>",
"      in vitro",
"     </i>",
"     (Li, 2004; Ogilvie, 2012), an",
"     <i>",
"      in vivo",
"     </i>",
"     study of extensive CYP2C19 metabolizers showed less reduction of the active metabolite of clopidogrel by lansoprazole/dexlansoprazole compared to esomeprazole/omeprazole (Frelinger, 2012). Avoidance of rabeprazole appears prudent due to potent",
"     <i>",
"      in vitro",
"     </i>",
"     CYP2C19 inhibition and lack of sufficient comparative",
"     <i>",
"      in vivo",
"     </i>",
"     studies with other PPIs.  In contrast to these warnings, others have recommended the continued use of PPIs, regardless of the degree of inhibition, in patients with multiple risk factors for GI bleeding who are also receiving clopidogrel since no evidence has established clinically meaningful differences in outcome; however, a clinically-significant interaction cannot be excluded in those who are poor metabolizers of clopidogrel. Staggering PPIs with clopidogrel is not recommended until further evidence is available (Abraham, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Reduced CYP2C19 function:",
"     <b>",
"      [U.S. Boxed Warning]: Patients with one or more copies of the variant",
"     </b>",
"     <b>",
"      <i>",
"       CYP2C19*2",
"      </i>",
"     </b>",
"     <b>",
"      and/or",
"     </b>",
"     <b>",
"      <i>",
"       CYP2C19*3",
"      </i>",
"     </b>",
"     <b>",
"      alleles (and potentially other reduced-function variants) may have reduced conversion of clopidogrel to its active thiol metabolite. Lower active metabolite exposure may result in reduced platelet inhibition and, thus, a higher rate of cardiovascular events following MI or stent thrombosis following PCI.",
"     </b>",
"     Although evidence is insufficient to recommend routine genetic testing, tests are available to determine CYP2C19 genotype and may be used to determine therapeutic strategy; alternative treatment or treatment strategies may be considered if patient is identified as a CYP2C19 poor metabolizer. Genetic testing may be considered prior to initiating clopidogrel in patients at moderate or high risk for poor outcomes (eg, PCI in patients with extensive and/or very complex disease). The optimal dose for CYP2C19 poor metabolizers has yet to be determined. After initiation of clopidogrel, functional testing (eg, VerifyNow&reg; P2Y12 assay) may also be done to determine clopidogrel responsiveness (Holmes, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Surgical patients: Consider discontinuing 5 days before elective surgery (except in patients with cardiac stents that have not completed their full course of dual antiplatelet therapy; patient-specific situations need to be discussed with cardiologist; AHA/ACC/SCAI/ACS/ADA Science Advisory provides recommendations). Discontinue at least 5 days before elective CABG; when urgent CABG is necessary, the ACCF/AHA CABG guidelines recommend discontinuation for at least 24 hours prior to surgery (Hillis, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery stents: Premature interruption of therapy may result in stent thrombosis with subsequent fatal and nonfatal MI. Duration of therapy, in general, is determined by the type of stent placed (bare metal or drug eluting) and whether an ACS event was ongoing at the time of placement.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F153651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2B6 (moderate), CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F153600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May diminish the therapeutic effect of Clopidogrel.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inhibitors (Moderate) may decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexlansoprazole: May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel.  Other acid-lowering therapies do not appear to share this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Esomeprazole: May decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lansoprazole: May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel.  Other acid-lowering therapies do not appear to share this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May diminish the therapeutic effect of Clopidogrel.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omeprazole: May decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pantoprazole: May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel.  Other acid-lowering therapies do not appear to share this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RABEprazole: May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel.  Other acid-lowering therapies do not appear to share this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May enhance the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Clopidogrel may enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F153623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, chamomile, coleus, cordyceps, dong quai, evening primrose oil, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American), ginseng (Panax), ginseng (Siberian), grape seed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), sweet clover, turmeric, white willow (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F153602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3343717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F153636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F153614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F153613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Clopidogrel Bisulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (30): $208.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $835.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Plavix Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (90): $696.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $928.13",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F153604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs of bleeding; hemoglobin and hematocrit periodically. May consider platelet function testing to determine platelet inhibitory response or genotyping for CYP2C19 loss of function variant if results of testing may alter management (Jneid, 2012).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F153615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actaclo (PH);",
"     </li>",
"     <li>",
"      Antiplar (PH);",
"     </li>",
"     <li>",
"      Apolets (TH);",
"     </li>",
"     <li>",
"      Artepid (ID);",
"     </li>",
"     <li>",
"      Ateplax (PE);",
"     </li>",
"     <li>",
"      Ceranade (KP);",
"     </li>",
"     <li>",
"      Ceruvin (TH);",
"     </li>",
"     <li>",
"      Cloart (KP);",
"     </li>",
"     <li>",
"      Clogin (ID);",
"     </li>",
"     <li>",
"      Clood (IL);",
"     </li>",
"     <li>",
"      Clopidexcel (IL);",
"     </li>",
"     <li>",
"      Clopilet (IN);",
"     </li>",
"     <li>",
"      Clopimet (PH);",
"     </li>",
"     <li>",
"      Clopistad (HK);",
"     </li>",
"     <li>",
"      Clopivas (HK);",
"     </li>",
"     <li>",
"      Clopivaz (PH);",
"     </li>",
"     <li>",
"      Clopivid (HK, MY);",
"     </li>",
"     <li>",
"      Clotinil (TW);",
"     </li>",
"     <li>",
"      Clotiz (PH);",
"     </li>",
"     <li>",
"      Clovixx (TW);",
"     </li>",
"     <li>",
"      Cotol (TW);",
"     </li>",
"     <li>",
"      CPG (ID);",
"     </li>",
"     <li>",
"      Curovix (KP);",
"     </li>",
"     <li>",
"      Deplat (TW);",
"     </li>",
"     <li>",
"      Deplatt (SG);",
"     </li>",
"     <li>",
"      Egitromb (BG);",
"     </li>",
"     <li>",
"      Hemaflow (PH);",
"     </li>",
"     <li>",
"      Hogel (CO);",
"     </li>",
"     <li>",
"      Iscover (AR, AT, AU, BE, BG, BR, CH, CZ, DE, DK, EE, ES, FR, GB, GR, IE, IT, MT, NO, PL, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Kogrel (MY);",
"     </li>",
"     <li>",
"      Kovix (KP);",
"     </li>",
"     <li>",
"      Lopirel (HK);",
"     </li>",
"     <li>",
"      Maxgrel (KP);",
"     </li>",
"     <li>",
"      Nabratin (CR, DO, GT, HN, NI, SV);",
"     </li>",
"     <li>",
"      Noclot (PK);",
"     </li>",
"     <li>",
"      Noklot (PH);",
"     </li>",
"     <li>",
"      Panagrel (PE);",
"     </li>",
"     <li>",
"      Piax (NZ);",
"     </li>",
"     <li>",
"      Pidogul (KP);",
"     </li>",
"     <li>",
"      Plabic (KP);",
"     </li>",
"     <li>",
"      Placta (ID, SG);",
"     </li>",
"     <li>",
"      Pladogrel (ID);",
"     </li>",
"     <li>",
"      Plagril (SG);",
"     </li>",
"     <li>",
"      Plamed (KP);",
"     </li>",
"     <li>",
"      PlaquEx (BG);",
"     </li>",
"     <li>",
"      Platogrix (ID);",
"     </li>",
"     <li>",
"      Platout (TW);",
"     </li>",
"     <li>",
"      Plavitor (KP);",
"     </li>",
"     <li>",
"      Plavix (AR, AT, AU, BB, BD, BE, BF, BG, BJ, BM, BO, BR, BS, BZ, CH, CI, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, ID, IE, IL, IT, JM, JP, KE, KP, LR, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PR, PT, PY, RU, SC, SD, SE, SG, SK, SL, SN, SR, SV, TH, TN, TR, TT, TW, TZ, UG, UY, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Plavos (ID);",
"     </li>",
"     <li>",
"      Provic (KP);",
"     </li>",
"     <li>",
"      Q.O.L. (KP);",
"     </li>",
"     <li>",
"      Ravalgen (EC);",
"     </li>",
"     <li>",
"      Simclovix (ID);",
"     </li>",
"     <li>",
"      Talcom (CL);",
"     </li>",
"     <li>",
"      Vaclo (ID);",
"     </li>",
"     <li>",
"      Vivelon (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F153594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clopidogrel requires",
"     <i>",
"      in vivo",
"     </i>",
"     biotransformation to an active thiol metabolite. The active metabolite irreversibly blocks the P2Y",
"     <sub>",
"      12",
"     </sub>",
"     component of ADP receptors on the platelet surface, which prevents activation of the GPIIb/IIIa receptor complex, thereby reducing platelet aggregation. Platelets blocked by clopidogrel are affected for the remainder of their lifespan (~7-10 days).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F153610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Inhibition of platelet aggregation (IPA): Dose-dependent:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300-600 mg loading dose: Detected within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-100 mg/day: Detected by the second day of treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak effect: Time to maximal IPA: Dose-dependent:",
"     <b>",
"      Note:",
"     </b>",
"     Degree of IPA based on adenosine diphosphate (ADP) concentration used during light aggregometry:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300-600 mg loading dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     ADP 5 micromole/L: 20% to 30% IPA at 6 hours post administration (Montelescot, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     ADP 20 micromole/L: 30% to 37% IPA at 6 hours post administration (Montelescot, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-100 mg/day: ADP 5 micromole/L: 50% to 60% IPA at 5-7 days (Herbert, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Parent drug: 98%; Inactive metabolite: 94%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via esterase-mediated hydrolysis to a carboxylic acid derivative (inactive) and via CYP450-mediated (CYP2C19 primarily) oxidation to a thiol metabolite (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Parent drug: ~6 hours; Active metabolite: ~30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~0.75 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (50%); feces (46%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      \"A Randomized, Blinded, Trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). CAPRIE Steering Committee,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 1996, 348(9083):1329-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/8918275/pubmed\" id=\"8918275\" target=\"_blank\">",
"        8918275",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Abraham NS, Hlatky MA, Antman EM, et al, &ldquo;ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(24):2619-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/21060077/pubmed\" id=\"21060077\" target=\"_blank\">",
"        21060077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, et al, \"Effect of Clopidogrel Added to Aspirin in Patients With Atrial Fibrillation,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(20):2066-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/19336502/pubmed\" id=\"19336502\" target=\"_blank\">",
"        19336502",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Adams HP, del Zoppo G, Alberts MJ, et al, \"Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups,\"",
"      <i>",
"       Stroke",
"      </i>",
"      , 2007, 38(5):1655-1711.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/17431204/pubmed\" id=\"17431204\" target=\"_blank\">",
"        17431204",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, The Society of Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 116(7):e148-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/17679616/pubmed\" id=\"17679616\" target=\"_blank\">",
"        17679616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Angiolillo DJ, Gibson CM, Cheng S, et al, &ldquo;Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2011, 89(1):65-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/20844485/pubmed\" id=\"20844485\" target=\"_blank\">",
"        20844485",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe DT, Armstrong PW, et al, \"ACC/AHA 2007 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2004, 44(3):671-719.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/15358045/pubmed\" id=\"15358045\" target=\"_blank\">",
"        15358045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bal dit Sollier C, Mahe I, Berge N, et al, \"Reduced Thrombus Cohesion in an",
"      <i>",
"       ex vivo",
"      </i>",
"      Human Model of Arterial Thrombosis Induced by Clopidogrel Treatment: Kinetics of the Effect and Influence of Single and Double Loading-Dose Regimens,\"",
"      <i>",
"       Thromb Res",
"      </i>",
"      , 2003, 111(1-2):19-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/14644074/pubmed\" id=\"14644074\" target=\"_blank\">",
"        14644074",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berger PB, Bell MR, Rihal CS, et al, \"Clopidogrel Versus Ticlopidine After Intracoronary Stent Placement,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 34(7):1891-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/10588199/pubmed\" id=\"10588199\" target=\"_blank\">",
"        10588199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bertrand ME, Rupprecht HJ, Urban P, et al, \"Double-Blind Study of the Safety of Clopidogrel With and Without a Loading Dose in Combination With Aspirin Compared With Ticlopidine in Combination With Aspirin After Coronary Stenting,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2000, 102(6):624-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/10931801/pubmed\" id=\"10931801\" target=\"_blank\">",
"        10931801",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Cryer BL, Contant CF, et al, \"Clopidogrel With or Without Omeprazole in Coronary Artery Disease,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 363(20):1909-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/20925534/pubmed\" id=\"20925534\" target=\"_blank\">",
"        20925534",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Fox KA, Hacke W, et al, \"Clopidogrel and Aspirin Versus Aspirin Alone for the Prevention of Atherothrombotic Events,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(16):1706-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/16531616/pubmed\" id=\"16531616\" target=\"_blank\">",
"        16531616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chen ZM, Jiang LX, Chen YP, et al, \"Addition of Clopidogrel to Aspirin in 45,852 Patients With Acute Myocardial Infarction: Randomized Placebo-Controlled Trial. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2005, 366(9497):1607-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/16271642/pubmed\" id=\"16271642\" target=\"_blank\">",
"        16271642",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, et al, \"Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 363(10):930-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/20818903/pubmed\" id=\"20818903\" target=\"_blank\">",
"        20818903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Desta Z, Zhao X, Shin JG, et al, \"Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2002, 41(12):913-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/12222994/pubmed\" id=\"12222994\" target=\"_blank\">",
"        12222994",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2012, 94(5):1761-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/23098967/pubmed\" id=\"23098967\" target=\"_blank\">",
"        23098967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frelinger AL 3rd, Lee RD, Mulford DJ, et al, \"A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2012, 59(14):1304-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/22464259/pubmed\" id=\"22464259\" target=\"_blank\">",
"        22464259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frere C, Cuisset T, Morange PE, et al, \"Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment with Clopidogrel in Acute Coronary Syndrome,\"",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 2008, 101(8):1088-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/18394438/pubmed\" id=\"18394438\" target=\"_blank\">",
"        18394438",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furie KL, Kasner SE, Adams RJ, et al, \"Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association,\"",
"      <i>",
"       Stroke",
"      </i>",
"      , 2011, 42(1):227-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/20966421/pubmed\" id=\"20966421\" target=\"_blank\">",
"        20966421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gilard M, Arnaud B, Cornily JC, et al, \"Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin: The Randomized, Double-Blind Ocla (Omeprazole Clopidogrel Aspirin) Study,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(3):256-60.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gilard M, Arnaud B, Le Gal G, et al, \"Influence of Omeprazol on the Antiplatelet Action of Clopidogrel Associated to Aspirin,\"",
"      <i>",
"       J Thromb Haemost",
"      </i>",
"      , 2006, 4(11):2508-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grines CL, Bonow RO, Casey DE, et al, \"AHA/ACC/SCAI/ACS/ADA Science Advisory, Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents. A Science Advisory From the American Heart Association, American College of Cardiology, Society of Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association With Representation from the Amercian College of Physicians,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115(6):813-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/17224480/pubmed\" id=\"17224480\" target=\"_blank\">",
"        17224480",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Herbert JM, Frehel D, Vallee E, et al, \"Clopidogrel, A Novel Antiplatelet and Antithrombotic Agent,\"",
"      <i>",
"       Cardiovascular Drug Rev",
"      </i>",
"      , 1993, 11(2):180-98.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al, &ldquo;ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic). A Collaborative Report of the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2006, 113(11):e463-654.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/16549646/pubmed\" id=\"16549646\" target=\"_blank\">",
"        16549646",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ho PM, Maddox TM, Wang L, et al, \"Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2009, 301(9):937-44.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochholzer W, Trenk D, Fromm MF, et al, \"Impact of Cytochrome P450 2C19 Loss-of-Function Polymorphism and of Major Demographic Characteristics on Residual Platelet Function After Loading and Maintenance Treatment with Clopidogrel in Patients Undergoing Elective Coronary Stent Placement,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2010, 55(22):2427-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/20510210/pubmed\" id=\"20510210\" target=\"_blank\">",
"        20510210",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochholzer W, Trenk D, Frundi D, et al, \"Time Dependence of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2005, 111(20):2560-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/15809367/pubmed\" id=\"15809367\" target=\"_blank\">",
"        15809367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holmes DR, Dehmer GJ, Kaul S, et al, \"ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA 'Boxed Warning.' A Report of the American College of Cardiology Foundation Task Force,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2010, 56(4):321-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/20585015 /pubmed\" id=\"20585015 \" target=\"_blank\">",
"        20585015",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jneid H, Anderson JL, Wright RS, et al, &ldquo;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(7):875-910.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/22800849/pubmed\" id=\"22800849\" target=\"_blank\">",
"        22800849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Juurlink DN, Gomes T, Ko DT, et al, \"A Population-Based Study of the Drug Interaction Between Proton Pump Inhibitors and Clopidogrel,\"",
"      <i>",
"       CMAJ",
"      </i>",
"      , 2009, 180(7):713-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/19176635/pubmed\" id=\"19176635\" target=\"_blank\">",
"        19176635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kastrati A, Mehilli J, Schuhlen H, et al, \"A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention After Pretreatment With Clopidogrel,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(3):232-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/14724302/pubmed\" id=\"14724302\" target=\"_blank\">",
"        14724302",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kreutz RP, Stanek EJ, Aubert R, et al, \"Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel After Coronary Stent Placement: The Clopidogrel Medco Outcomes Study,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2010, 30(8):787-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/20653354/pubmed\" id=\"20653354\" target=\"_blank\">",
"        20653354",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lange RA and Hillis LD, \"Antiplatelet Therapy for Ischemic Heart Disease,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(3):277-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/14724308/pubmed\" id=\"14724308\" target=\"_blank\">",
"        14724308",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lidell C, Svedberg LE, Lindell P, et al, \"Clopidogrel and Warfarin: Absence of Interaction in Patients Receiving Long-Term Anticoagulant Therapy for Nonvalvular Atrial Fibrillation,\"",
"      <i>",
"       Thromb Haemost",
"      </i>",
"      , 2003, 89(5):842-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/12719782/pubmed\" id=\"12719782\" target=\"_blank\">",
"        12719782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Li XQ, Andersson TB, Ahalstr&ouml;m M, et al, \"Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole and Rabeprazole on Human Cytochrome P450 Activities,\"",
"      <i>",
"       Drug Metab Dispo",
"      </i>",
"      , 2004, 32(8):821-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/15258107/pubmed\" id=\"15258107\" target=\"_blank\">",
"        15258107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mega JL, Close SL, Wiviott SD, et al, \"Cytochrome P-450 Polymorphisms and Response to Clopidogrel,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(40):354-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/19106084/pubmed\" id=\"19106084\" target=\"_blank\">",
"        19106084",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mehta SR, Yusuf S, Peters RJ, et al, \"Effects of Pretreatment With Clopidogrel and Aspirin Followed by Long-Term Therapy in Patients Undergoing Percutaneous Coronary Intervention: The PCI-CURE Study,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2001, 358(9281):527-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/11520521/pubmed\" id=\"11520521\" target=\"_blank\">",
"        11520521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mishkel GJ, Aguirre FV, Ligon RW, et al, \"Clopidogrel as Adjunctive Antiplatelet Therapy During Coronary Stenting,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 34(7):1884-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/10588198/pubmed\" id=\"10588198\" target=\"_blank\">",
"        10588198",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Montalescot G, Sideris G, Meuleman C, et al, \"A Randomized Comparison of High Clopidogrel Loading Doses in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(5):931-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/16949482/pubmed\" id=\"16949482\" target=\"_blank\">",
"        16949482",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moussa I, Oetgen M, Roubin G, et al, \"Effectiveness of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin in Preventing Stent Thrombosis After Coronary Stent Implantation,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 99(18):2364-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/10318654/pubmed\" id=\"10318654\" target=\"_blank\">",
"        10318654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O&rsquo;Donoghue ML, Braunwald E, Antman EM, et al, \"Pharmacodynamic Effect and Clinical Efficacy of Clopidogrel and Prasugrel with or without a Proton-pump Inhibitor: an Analysis of Two Randomised Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9694):989-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/19726078/pubmed\" id=\"19726078\" target=\"_blank\">",
"        19726078",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ogilvie BW, Yerino P, Kazmi F, et al, &ldquo;The Proton Pump Inhibitor, Omeprazole, but not Lansoprazole or Pantoprazole, is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration With Clopidogrel,&rdquo;",
"      <i>",
"       Drug Metab Dispos",
"      </i>",
"      , 2011, 39(11):2020-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/21795468/pubmed\" id=\"21795468\" target=\"_blank\">",
"        21795468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patti G, Colonna G, Pasceri V, et al, \"Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty) Study,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2005, 111(16):2099-106.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pezalla E, Day D, and Pulliadath I, \"Initial Assessment of Clinical Impact of a Drug Interaction Between Clopidogrel and Proton Pump Inhibitors,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(12):1038-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Price MJ, Berger PB, Teirstein PS, et al, \"Standard- Vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention: The GRAVITAS Randomized Trial,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2011, 305(11):1097-105.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/21406646/pubmed\" id=\"21406646\" target=\"_blank\">",
"        21406646",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rooke TW, Hirsch AT, Misra S, et al, &ldquo;2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(18):2020-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/21959305/pubmed\" id=\"21959305\" target=\"_blank\">",
"        21959305",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sabatine MS, Cannon CP, Gibson CM, et al, \"Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction With ST-Segment Elevation,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(12):1179-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/15758000/pubmed\" id=\"15758000\" target=\"_blank\">",
"        15758000",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scirica BM, Sabatine MS, Morrow DA, et al, \"The Role of Clopidogrel in Early and Sustained Arterial Patency After Fibrinolysis for ST-segment Elevation Myocardial Infarction. The ECG Clarity-TIMI 28 Study,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(1):37-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/16814646/pubmed\" id=\"16814646\" target=\"_blank\">",
"        16814646",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sibbing D, Koch W, Gebhard D, et al, \"Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 121(4):512-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/20083681/pubmed\" id=\"20083681\" target=\"_blank\">",
"        20083681",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Siller-Matula JM, Spiel AO, Lang IM, et al, \"Effects of Pantoprazole and Esomeprazole on Platelet Inhibition by Clopidogrel,\"",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 2009, 157(1):148.e1-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sim SC, Risinger C, Dahl ML, et al, \"A Common Novel CYP2C19 Gene Variant Causes Ultrarapid Drug Metabolism Relevant for the Drug Response to Proton Pump Inhibitors and Antidepressants,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2006, 79(1):103-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/16413245/pubmed\" id=\"16413245\" target=\"_blank\">",
"        16413245",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2012, 28(2):125-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/22433576/pubmed\" id=\"22433576\" target=\"_blank\">",
"        22433576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Small DS, Farid NA, Payne CD, et al, \"Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2008, 48(4):475-84.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      SPS3 Investigators, &ldquo;Effects of Clopidogrel Added to Aspirin in Patients With Recent Lacunar Stroke,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 367(9):817-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/22931315/pubmed\" id=\"22931315\" target=\"_blank\">",
"        22931315",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steinhubl SR, Berber PB, Mann JT, et al, \"Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention. A Randomized Controlled Trial,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(19):2411-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/12435254/pubmed\" id=\"12435254\" target=\"_blank\">",
"        12435254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trenk D, Hochholzer W, Fromm MF, et al, \"Cytochrome P450 2C19 681G&gt;A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug Eluting or Bare-Metal Stents,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(20):1925-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/18482659/pubmed\" id=\"18482659\" target=\"_blank\">",
"        18482659",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yusuf S, Zhao F, Mehta SR, et al, \"Effects of Clopidogrel in Addition to Aspirin in Patients With Acute Coronary Syndromes Without ST-Segment Elevation,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(7):494-502.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/9/34969/abstract-text/11519503/pubmed\" id=\"11519503\" target=\"_blank\">",
"        11519503",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8921 Version 55.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-DE6246C94F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_9_34969=[""].join("\n");
var outline_f34_9_34969=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10072956\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153626\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153627\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153658\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153630\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153631\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153632\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153633\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153606\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153591\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11566548\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9480379\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153608\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153654\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153666\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153656\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153611\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153595\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153651\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153600\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153623\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153602\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343717\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153636\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153614\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153613\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153604\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153615\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153594\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153610\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8921\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8921|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/11/21685?source=related_link\">",
"      Clopidogrel: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/49/16152?source=related_link\">",
"      Clopidogrel: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_9_34970="Definition, pathogenesis, and etiology of polycystic ovary syndrome in adolescents";
var content_f34_9_34970=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Definition, pathogenesis, and etiology of polycystic ovary syndrome in adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/9/34970/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/9/34970/contributors\">",
"     Robert L Rosenfield, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/9/34970/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/9/34970/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/9/34970/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/9/34970/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/9/34970/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/9/34970/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycystic ovary syndrome (PCOS) accounts for the vast majority of anovulatory symptoms and hyperandrogenism in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The diagnosis of PCOS has life-long implications with increased risk for infertility, metabolic syndrome, type 2 diabetes mellitus, and possibly cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. It should be considered in any adolescent girl with hirsutism, persistent acne, menstrual irregularity, or obesity.",
"   </p>",
"   <p>",
"    The definition, pathophysiology, and etiology of PCOS in adolescents will be presented here. The clinical features, diagnosis, and treatment of PCOS in adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/13/39130?source=see_link\">",
"     \"Clinical features and diagnosis of polycystic ovary syndrome in adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24297?source=see_link\">",
"     \"Treatment of polycystic ovary syndrome in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic syndrome originally was described by Stein and Leventhal as the association of amenorrhea with polycystic ovaries, and variably, hirsutism and obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/6\">",
"     6",
"    </a>",
"    ]. It is now recognized that polycystic ovary syndrome (PCOS) represents a spectrum of disease characterized primarily by the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cutaneous hyperandrogenism (eg, hirsutism, treatment-resistant acne,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      male- or female-pattern balding [androgenetic alopecia])",
"     </li>",
"     <li>",
"      Menstrual irregularity (eg, oligo- or amenorrhea, or irregular bleeding)",
"     </li>",
"     <li>",
"      Polycystic ovaries (one or both)",
"     </li>",
"     <li>",
"      Obesity and insulin resistance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to appreciate that PCOS is a syndrome, not a disease, reflecting multiple potential etiologies with variable clinical expression of these and other features in adolescents with PCOS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/13/39130?source=see_link\">",
"     \"Clinical features and diagnosis of polycystic ovary syndrome in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of this clinical heterogeneity, it is sometimes challenging to diagnose PCOS because most cases will not have all of the primary features. As an example, patients often present with hirsutism without symptoms of anovulation or with menstrual irregularity without hirsutism, and many do not have polycystic ovaries or obesity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three sets of diagnostic criteria have been developed to identify and diagnose patients with PCOS (",
"    <a class=\"graphic graphic_table graphicRef80095 \" href=\"mobipreview.htm?11/29/11740\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     NIH criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1990, the National Institutes of Health (NIH) Conference on PCOS defined PCOS as chronic, otherwise unexplained hyperandrogenism and evidence of anovulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/7\">",
"     7",
"    </a>",
"    ]. Hyperandrogenism could be defined by either clinical or biochemical findings. Anovulation usually presents in adolescence as an abnormal degree of menstrual irregularity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/8\">",
"     8",
"    </a>",
"    ]. This is the most widely accepted set of criteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Rotterdam criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2003, the European Society of Human Reproduction and Embryology",
"    <span class=\"nowrap\">",
"     (ESHRE)/American",
"    </span>",
"    Society of Reproductive Medicine (ASRM) consensus workshop group added a polycystic ovary (or ovaries) as an alternative finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/9\">",
"     9",
"    </a>",
"    ]. This criterion was added to address the diagnostic problem presented by the 10 percent of PCOS cases that are ovulatory but subfertile. The Rotterdam criteria define PCOS when two of the three primary features are present: unexplained clinical or biochemical signs of hyperandrogenism, oligo-anovulation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a polycystic ovary. Thus, the Rotterdam criteria included two groups of patients who do not fulfill the NIH criteria: 1) patients with a polycystic ovary who are hyperandrogenic but ovulate normally, and 2) patients with anovulatory dysfunction and a polycystic ovary but no evidence of hyperandrogenism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     The Androgen Excess and PCOS Society (AES) criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Androgen Excess Society (AES) addressed the differences between the Rotterdam and NIH criteria in 2006 and issued an updated report in 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/10\">",
"     10",
"    </a>",
"    ]. They endorsed the NIH criteria and broadened them to include the Rotterdam criterion of a polycystic ovary. In other words, they considered a polycystic ovary to be an alternative to oligo-anovulation as evidence of ovarian dysfunction in the setting of hyperandrogenism. However, they considered PCOS to be a hyperandrogenic disorder, and disputed the Rotterdam criterion that permitted PCOS to be diagnosed solely on the combination of oligo-anovulation and a polycystic ovary, arguing that this was too nonspecific and not necessarily due to androgen excess.",
"   </p>",
"   <p>",
"    Although these criteria recognize much of the clinical heterogeneity of the syndrome, the following diagnostic controversies remain:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is disagreement over whether the combination of oligo-anovulation and polycystic ovaries, without evidence of hyperandrogenism, represents a subtle form of PCOS.",
"     </li>",
"     <li>",
"      Equating clinical evidence of hyperandrogenism (eg, hirsutism) with biochemical evidence of hyperandrogenism (eg, hyperandrogenemia) is not optimal. Mild hirsutism is an inaccurate surrogate for hyperandrogenemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. The degree of hirsutism does not always correlate with the level of androgens because hair follicle response to androgens varies among individuals. As a result, some patients will develop hirsutism with normal levels of androgens (ie, idiopathic hirsutism).",
"     </li>",
"     <li>",
"      Biochemical hyperandrogenism and the polycystic ovary may be difficult to document because reliable methodology or expertise is not widely available.",
"     </li>",
"     <li>",
"      Whether obesity and insulin resistance are fundamentally related to PCOS remains unclear. The reported prevalence of obesity in PCOS varies from 30 to 75 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/13\">",
"       13",
"      </a>",
"      ]. The use of body mass index (BMI) to define obesity is problematic because two-thirds of those patients with PCOS who are not obese have been reported to have excessive body fat and central adiposity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/14\">",
"       14",
"      </a>",
"      ]. About 50 to 75 percent of PCOS patients have an abnormal degree of insulin resistance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/15\">",
"       15",
"      </a>",
"      ]. Insulin resistance is significantly increased for the degree of adiposity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/16-20\">",
"       16-20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Obesity may mimic PCOS in some cases, rather than be a fellow traveler. In our series of PCOS patients who met NIH diagnostic criteria, an obese subset was atypical in having neither an identifiable ovarian nor adrenal source for androgen excess [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/21\">",
"       21",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Functional ovarian hyperandrogenism (FOH)'",
"      </a>",
"      below). We have postulated that their excess adipose tissue was both the cause of the testosterone excess (since fat tissue has the capacity to convert circulating androstenedione to testosterone), and also the cause of the ovulatory dysfunction (via the suppressive effect of obesity on luteinizing hormone (LH) levels).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;No formal diagnostic criteria have been established for PCOS in adolescents. In the absence of a consensus for this age group, the NIH criteria for the diagnosis of PCOS are preferred in adolescents. That is, PCOS is diagnosed in girls with the following features, if these clinical findings are not otherwise explained:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperandrogenism, preferably confirmed by specific biochemical testing",
"      <br/>",
"      <br/>",
"      <strong>",
"       AND",
"      </strong>",
"     </li>",
"     <li>",
"      An abnormal menstrual pattern (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/13/39130?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical features and diagnosis of polycystic ovary syndrome in adolescents\", section on 'Ovarian findings'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of only Rotterdam-AES criteria for the diagnosis of PCOS (ie, on the basis of a polycystic ovary and hyperandrogenism without menstrual abnormality) is controversial in adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/22\">",
"     22",
"    </a>",
"    ]. These criteria are sometimes met by asymptomatic girls; it has been postulated that such subjects may be carriers for or at risk of PCOS. On the other hand, they are potentially useful in eumenorrheic adolescents with symptomatic hyperandrogenism (eg, hirsutism), in whom these criteria permit a provisional diagnosis of PCOS, contingent upon confirmation by demonstration of long-term persistence of hyperandrogenism and the polycystic ovary.",
"   </p>",
"   <p>",
"    The strength of the AES criterion that a polycystic ovary substitutes for anovulation as evidence of the ovarian dysfunction of PCOS (and the comparable Rotterdam criterion) is that it addresses the following areas of uncertainty about the diagnosis in adolescents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anovulation &mdash; The diagnosis of &ldquo;ovulatory PCOS&rdquo; can be made in a hyperandrogenic adult in the presence of normal ovulatory cycles if a polycystic ovary is demonstrated.",
"     </li>",
"     <li>",
"      Ovarian follicles &mdash; It provides consensus about the definition of a polycystic ovary in adults. An excess follicle number (a \"polyfollicular\" ovary) in the absence of excessive size has now been defined in adults, by international consensus, as a type of polycystic ovary [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/23\">",
"       23",
"      </a>",
"      ]. This definition encompasses some ovaries formerly termed \"multifollicular\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/24\">",
"       24",
"      </a>",
"      ], a term now obsolete. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/13/39130?source=see_link&amp;anchor=H30#H30\">",
"       \"Clinical features and diagnosis of polycystic ovary syndrome in adolescents\", section on 'Ultrasonography'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The weakness of the AES criterion that a polycystic ovary substitutes for anovulation as evidence of the ovarian dysfunction of PCOS is the possibility of over-diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polycystic ovaries are commonly normal variants &mdash; A polycystic ovary is often a normal variant. In half of normal volunteers who possess a polycystic ovary, no evidence of ovarian androgenic dysfunction was found [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/25\">",
"       25",
"      </a>",
"      ]. Thus, the possibility of a polycystic ovary as a coincidental finding is relatively high. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/13/39130?source=see_link&amp;anchor=H30#H30\">",
"       \"Clinical features and diagnosis of polycystic ovary syndrome in adolescents\", section on 'Ultrasonography'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The questionable prognosis of asymptomatic PCOS &mdash; A substantial minority of asymptomatic regularly menstruating volunteers with a polycystic ovary have an elevated plasma free testosterone level [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/26\">",
"       26",
"      </a>",
"      ] and thus meet AES criteria for PCOS. They typically also have functional ovarian hyperandrogenism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/25\">",
"       25",
"      </a>",
"      ]. However, it is unclear whether a diagnosis of PCOS in these subjects is of clinical significance. Thus, the application of AES criteria in this setting carries prognostic uncertainty. It seems best to view such girls as being",
"      <strong>",
"       at",
"      </strong>",
"      <strong>",
"       <em>",
"       </em>",
"      </strong>",
"      <strong>",
"       risk",
"      </strong>",
"      of PCOS or carriers for PCOS, rather than assigning a diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/13/39130?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical features and diagnosis of polycystic ovary syndrome in adolescents\", section on 'Ovarian findings'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    None of the three sets of diagnostic criteria described above for adults address the following unique issues in diagnosing PCOS in adolescents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uncertainty about the non-physiologic nature of mild degrees of oligomenorrhea (menses at more than 45-day, but less than 90-day intervals) in the first two post-menarcheal years.",
"     </li>",
"     <li>",
"      The relationship of common (\"physiologic\") adolescent anovulation to PCOS is unclear. In adolescent girls without clinical features of PCOS, approximately one-half of regular menstrual cycles are normally asymptomatically anovulatory in the first two years after menarche [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/27\">",
"       27",
"      </a>",
"      ]. On the other hand, the meager available data indicate that about half of adolescents with symptomatic anovulation (ie, menstrual irregularity) have biochemical characteristics of PCOS, although they lack the clinical features [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/28,29\">",
"       28,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Uncertainty about the role of polycystic ovarian morphology in diagnosis. There is no consensus about whether adult ovarian size criteria are appropriate for adolescents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/22,30,31\">",
"       22,30,31",
"      </a>",
"      ]. Furthermore, polycystic ovarian morphology is not highly stable during adolescence. A longitudinal study of normal, regularly menstruating adolescents commencing two years after menarche found that the concordance between ultrasonographic diagnosis of a polycystic ovary at two and four years postmenarche (50 percent) was nonsignificant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/30\">",
"       30",
"      </a>",
"      ]. This inconstancy indicates that a polycystic ovary may be a transient finding during adolescence, although a cross-sectional study has suggested a similar prevalence in adolescent and adult volunteers.",
"     </li>",
"     <li>",
"      Unstable morphology may explain why in some series of adolescent volunteers the polycystic ovaries are predominantly ascertained on the basis of size criteria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/31\">",
"       31",
"      </a>",
"      ] and in others on the basis of follicle criteria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chronicity &mdash; PCOS in adults is a chronic condition. However, the natural history of PCOS diagnosed in adolescence is not well-documented. The meager available evidence indicates that once hyperandrogenemia develops, it seldom regresses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Because of the controversies and uncertainties surrounding the diagnosis, it has been argued that the diagnosis of PCOS can be made with certainty in an adolescent only in the presence of hyperandrogenemia, oligo-anovulation for two years or more, and ovarian enlargement, and that the NIH criteria alone provide only provisional evidence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/22\">",
"       22",
"      </a>",
"      ]. In our view, the diagnosis can be made within the first two years after menarche by NIH criteria if interpreted using adolescent norms, since girls within the early post-menarcheal years who meet these criteria are similar to adult women with PCOS in ovarian biochemical dysfunction and morphology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. Without doubt, studies of the natural history of adolescent PCOS are needed to clarify this.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other forms of PCOS may exist in the absence of symptomatic or ultrasonographic evidence of ovarian dysfunction if dynamic testing yields laboratory evidence of the PCOS-type of functional ovarian or adrenal hyperandrogenism, as discussed below. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Abnormal steroidogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraovarian androgen excess appears to be responsible for both anovulation and the formation of multiple ovarian \"cysts\" (which are actually small ovarian follicles that are hindered in developing a dominant follicle). There is vigorous debate about whether this pathologic process is primarily a disorder of pituitary gonadotropin secretion or a disorder of ovarian",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adrenal steroidogenesis. In addition, there is evidence that PCOS may result from a metabolic disorder that includes insulin resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Abnormal pituitary function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased luteinizing hormone (LH) relative to follicle-stimulating hormone (FSH) was the first laboratory abnormality identified in classic PCOS. Elevated LH levels occur in about half of PCOS patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/26,34\">",
"     26,34",
"    </a>",
"    ]. Elevated LH is thought to play a role in the pathogenesis of PCOS by increasing androgen production and secretion by ovarian theca cells (",
"    <a class=\"graphic graphic_figure graphicRef57364 \" href=\"mobipreview.htm?38/31/39423\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Patients with PCOS have an increased LH pulse frequency and amplitude [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increase in LH may be the result of abnormal sex steroid feedback, rather than the cause of androgen excess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/37\">",
"     37",
"    </a>",
"    ]. A modest rise in androgen levels normally stimulates LH pulsatility rather than suppresses it, which requires a substantial elevation. Patients with PCOS are less sensitive to suppression of the LH pulse frequency by sex steroids, as compared with controls. Furthermore, antiandrogen treatment normalizes the inhibitory effect of progesterone on elevated LH pulse frequency. These results suggest that androgen excess increases LH pulse frequency by interfering with the hypothalamic inhibitory feedback of progesterone.",
"   </p>",
"   <p>",
"    Obesity seems to attenuate the increase in LH pulse amplitude, in part because the pituitary gonadotrophs of obese women with PCOS produce LH isoforms that are rapidly metabolized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/37\">",
"     37",
"    </a>",
"    ]. On the other hand, LH is increased in a mouse model of dietary obesity in which the gonadotroph maintains insulin sensitivity in a state of peripheral insulin resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/38\">",
"     38",
"    </a>",
"    ]. Thus, the precise role of obesity and insulin in regulation of gonadotropin secretion has yet to be delineated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hypothesis that PCOS is primarily caused by abnormal pituitary function does not account for the half of patients with PCOS who do not have elevated LH levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/35,37\">",
"     35,37",
"    </a>",
"    ]. Furthermore, half of subjects with the PCOS-type of ovarian hyperandrogenism demonstrated by gonadotropin-releasing hormone (GnRH) agonist testing have normal LH levels, suggesting that their ovarian dysfunction is independent of LH excess.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Abnormal steroidogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;We favor the alternative hypothesis that PCOS is due to intrinsic ovarian dysfunction. This hypothesis considers that primary functional ovarian hyperandrogenism (FOH) is the essence of PCOS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/35,36,40\">",
"     35,36,40",
"    </a>",
"    ]. The intraovarian level of androgens in FOH is higher than in most adrenal causes of androgen excess. This results in excessive growth of small ovarian follicles while inhibiting follicular maturation and development of the dominant follicle and also stimulates premature luteinization of theca and granulosa cells along with stromal and cortical hyperplasia. These result in the polycystic appearance of the ovary and the anovulatory symptoms. Excess androgen also causes thecal and stromal hyperplasia.",
"   </p>",
"   <p>",
"    LH is necessary for the expression of gonadal steroidogenic enzymes and sex hormone secretion. Consequently, PCOS is LH-dependent (ie, &ldquo;functional&rdquo;), and any treatment that suppresses LH levels suppresses ovarian steroidogenesis.",
"   </p>",
"   <p>",
"    Increases in LH above adult steady-state levels normally cause homologous desensitization of theca cells, which limits the steroidogenic response. Consequently, half-maximal LH or human chorionic gonadotropin (hCG) stimulation normally causes little rise in serum androgen or estrogen levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/35,41-43\">",
"     35,41-43",
"    </a>",
"    ]. Desensitization involves down-regulation of LH receptor expression and steroidogenesis. In contrast, in functionally typical PCOS, there is a partial &ldquo;escape&rdquo; from down-regulation because of dysregulation of steroidogenesis, with the consequence that ovarian steroids are hypersensitive to LH.",
"   </p>",
"   <p>",
"    Two lines of evidence suggest that PCOS is caused by intrinsic ovarian steroidogenic dysfunction. First, in vivo evidence has shown FOH to be typified by abnormal steroidogenic sensitivity to gonadotropins that persists after prolonged gonadotropin suppression, and there is a parallel functional adrenal hyperandrogenism (FAH). Second, in vitro studies have shown that an abnormal steroidogenic phenotype is present in isolated theca cells and persists through long-term passage in culture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Functional ovarian hyperandrogenism (FOH)",
"    </span>",
"    &nbsp;&mdash;&nbsp;About two-thirds of PCOS cases meeting NIH criteria for the diagnosis have a functionally typical type of FOH in which there is 17-hydroxyprogesterone (17-OHP) hyperresponsiveness and hypersensitivity to LH, as indicated by GnRH agonist or hCG testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/26,35,36,41\">",
"     26,35,36,41",
"    </a>",
"    ]. This type of FOH is characterized by an elevated 17-OHP without evidence of a steroidogenic block; indeed, estradiol hyper-responds to GnRH agonist testing and is hypersensitive to submaximal hCG stimulation. FSH does not inhibit androgen output, as it does in controls. In a series of 60 PCOS patients with hyperandrogenic anovulation between 12 and 38 years of age, two-thirds were typical 17-OHP hyper-responders.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    suppression testing demonstrated persistent elevation of plasma testosterone after inhibition of adrenocortical function in 90 percent of this group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/21\">",
"     21",
"    </a>",
"    ]. Ninety-five percent had a polycystic ovary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The remaining one-third of the PCOS cases in this series was functionally atypical in that 17-OHP hyper-responsiveness to gonadotropins was lacking. Hyperandrogenism was significantly milder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/21\">",
"     21",
"    </a>",
"    ], and a polycystic ovary was found significantly less often (67 percent) than in functionally typical PCOS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/25\">",
"     25",
"    </a>",
"    ]. They were significantly more obese, but similarly insulin resistant, and yet had significantly less glucose intolerance. This itself is a heterogeneous group. Sixty percent of this group had an atypical form of FOH, as indicated by an abnormal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    androgen-suppression test. In contrast, in 40 percent of this group, FOH could not be demonstrated by either the GnRH agonist test or the dexamethasone suppression test, although most had a polycystic ovary. A minority of this &ldquo;non-ovarian PCOS&rdquo; group had isolated FAH, while in the majority the source of androgen was unexplained, and their androgen excess was postulated to be due to obesity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Functional adrenal hyperandrogenism (FAH)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PCOS also have a characteristic type of adrenal dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Hyper-responsiveness and hypersensitivity to adrenocorticotropic hormone (ACTH) usually coexist with FOH, but may occur in the absence of FOH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/21\">",
"     21",
"    </a>",
"    ]. This primary FAH consists of moderately excessive responses of weak androgens and their precursors, particularly dehydroepiandrosterone (DHEA) and 17-hydroxypregnenolone, to ACTH without evidence of a block in steroidogenesis. This type of steroidogenic dysfunction is demonstrated more often by a high-dose (46 percent) than by a low-dose (28 percent) ACTH test. In the past, FAH often was mistaken for deficiency of 3&szlig;-hydroxysteroid dehydrogenase, which is now known to be a rare disorder of steroidogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/44\">",
"     44",
"    </a>",
"    ]. FAH also has been suspected of being \"exaggerated adrenarche\" (a severe form of the normal developmental variant of premature adrenarche). However, this explanation seems less likely, because in 20 to 59 percent of patients with FAH, DHEA sulfate is normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/21,35\">",
"     21,35",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/62/21481?source=see_link\">",
"     \"Premature adrenarche\"",
"    </a>",
"    ). Many FAH patients have a functional polymorphism of 11&szlig;-hydroxysteroid dehydrogenase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Intrinsic factors underlying dysregulated steroidogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian function test data indicate that the ovary typically is hypersensitive to gonadotropin stimulation because of dysregulation of steroidogenesis. This dysregulation appears to cause a defect in down-regulation of responsiveness to LH and has been postulated to underlie the adrenal androgenic hyperresponsiveness to ACTH.",
"   </p>",
"   <p>",
"    Dysregulation of steroidogenesis is postulated to result from imbalance among the various intrinsic and extrinsic factors involved in the modulation of trophic hormone synthesis and action. The major site of theca cell dysregulation occurs at cytochrome P450c17, which has both 17-hydroxylase and 17,20 lyase activity (",
"    <a class=\"graphic graphic_figure graphicRef57364 \" href=\"mobipreview.htm?38/31/39423\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. The latter enzymatic activity is the rate-limiting step in androgen formation both in the ovaries and adrenal glands. This dysregulation seems to cause patterns of overactive steroidogenesis that are gland-specific, dependent on trophic hormones, and occur in the absence of evidence of a steroidogenic block. Changes in the steroid hormone biochemical pathways and metabolism in patients with PCOS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/12?source=see_link\">",
"     \"Steroid hormone metabolism in polycystic ovary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Androgen is a necessary evil in the ovary: it is required as the substrate for estrogen formation, but excessive androgen causes follicular maturation arrest. Normally, the thecal androgenic response to LH seems to be coordinated with granulosa cell needs by paracrine mechanisms rather than by long-loop negative feedback. The paracrine factors involved are sex steroids and a variety of peptides, including the",
"    <span class=\"nowrap\">",
"     insulin/insulin-like",
"    </span>",
"    growth factors (IGF) and the",
"    <span class=\"nowrap\">",
"     inhibin/activin",
"    </span>",
"    systems. In patients with PCOS, the processes that normally coordinate androgen and estrogen secretion within the ovary appear to be defective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/35,41\">",
"     35,41",
"    </a>",
"    ]. These defects cause the ovaries to over-respond to LH stimulation, as opposed to the normal down-regulation response that limits androgen secretion when LH rises above the steady-state level.",
"   </p>",
"   <p>",
"    In vitro studies have provided convincing evidence that an inherent thecal cell defect is central to excess androgen production. They show that thecal cell dysfunction is associated with overexpression of most steroidogenic enzymes, particularly cytochrome P450c17 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. This distinct abnormal biochemical and molecular phenotype is retained in long-term cultured cell lines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/46,47,49\">",
"     46,47,49",
"    </a>",
"    ]. Insulin-like factor 3 has emerged as another dysregulated thecal cell product [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adrenal dysregulation in PCOS, similar to ovarian thecal cell dysregulation, may have an intrinsic basis. Among many factors involved in the intra-adrenal modulation of the 17-ketosteroid response to ACTH, interleukin-6 is expressed strongly in the zona reticularis of the adrenal cortex and is capable of selectively stimulating DHEA secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H121492970\">",
"    <span class=\"h3\">",
"     Extrinsic factors contributing to dysregulated steroidogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     insulin/IGF",
"    </span>",
"    system is capable of acting in synergy with trophic hormones, contributing to ovarian or adrenal excess androgen production. In the ovary, insulin acts in conjunction with LH to enhance androgen production and reverse the LH-induced down-regulation of LH binding sites (",
"    <a class=\"graphic graphic_figure graphicRef57364 \" href=\"mobipreview.htm?38/31/39423\">",
"     figure 1",
"    </a>",
"    ). Insulin and IGFs increase the activities of multiple steroidogenic enzymes in both the ovaries and adrenal glands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/35,36,52\">",
"     35,36,52",
"    </a>",
"    ]. Testosterone formation by steroidogenic cells is up-regulated by insulin, mediated by a transcription factor involved in adipogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/52\">",
"     52",
"    </a>",
"    ]. This suggests that the hyperandrogenemia and obesity of PCOS are mechanistically linked (see",
"    <a class=\"local\" href=\"#H11771185\">",
"     'Insulin resistant hyperinsulinism'",
"    </a>",
"    below). Inflammatory cytokines such as tumor necrosis factor-alpha (TNF-&alpha;) also stimulate steroidogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/36,53\">",
"     36,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H121493091\">",
"    <span class=\"h3\">",
"     Other organs contributing to dysregulated steroidogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence that hepatic, skin, and adipose tissue metabolism of steroid precursors contributes to the androgen excess of PCOS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/36\">",
"     36",
"    </a>",
"    ]. These steroidogenic disturbances may, in part, be secondary to the hyperinsulinism and in part to androgen excess itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H121493139\">",
"    <span class=\"h3\">",
"     Granulosa cell dysfunction and increased folliculogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian granulosa cell functions also appear to be defective in PCOS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/35,41\">",
"     35,41",
"    </a>",
"    ]. Granulosa cells in patients with PCOS over-express the LH receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/48\">",
"     48",
"    </a>",
"    ] and 5&alpha;-reductase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/56\">",
"     56",
"    </a>",
"    ]. They often overproduce estradiol in response to high levels of FSH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/41,57,58\">",
"     41,57,58",
"    </a>",
"    ]. This seems to contribute to the increased risk of developing ovarian hyperstimulation syndrome during fertility treatment in women with PCOS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/17/16660?source=see_link\">",
"     \"Pathogenesis of ovarian hyperstimulation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increased responsiveness of the granulosa cells to gonadotropins may be, in part, because of an increase in the number of small follicles. While this may be in turn secondary to androgen excess promoting the number of small follicles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/40\">",
"     40",
"    </a>",
"    ], the possibility exists that these granulosa cell abnormalities may reflect an intrinsic defect in the intraovarian regulation of early folliculogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/41\">",
"     41",
"    </a>",
"    ]. Small antral follicle function is increased, as indicated by inhibin B hyper-responsiveness to FSH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/59\">",
"     59",
"    </a>",
"    ] that persists after long-term gonadotropin suppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This granulosa cell dysfunction appears to contribute to theca cell overproduction of androgens. Clinical observations and animal studies suggest that theca cell function is modulated by paracrine factors produced by granulosa cells in response to FSH, and inhibin B is a prime mediator (",
"    <a class=\"graphic graphic_figure graphicRef57364 \" href=\"mobipreview.htm?38/31/39423\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The testosterone excess of PCOS falls by one-half during menopause [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with inactivating mutations of FSH have no clinical evidence of hyperandrogenism, despite very high levels of LH. When exogenous FSH was given to such a patient, inhibin B rose 10-fold, and the response of thecal cell steroids to hCG markedly increased [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In typical FOH, FSH does not inhibit thecal testosterone production as it normally should, and this seems attributable to inhibin B hyper-responsiveness to FSH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/41\">",
"       41",
"      </a>",
"      ]. Thus, in response to LH, thecal androgenic substrate is allowed to rise sufficiently to drive inappropriate granulosa cell estradiol secretion, without the normal need for FSH up-regulation of aromatase. The hyper-responsiveness of estradiol and inhibin B to gonadotropins would seem to combine in their negative feedback effect on FSH and contribute to its low level in typical PCOS.",
"     </li>",
"     <li>",
"      Asymptomatic eumenorrheic volunteers with a polycystic ovary often have a 17-OHP response to GnRH agonist testing just like PCOS, even though they are not hyperandrogenic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/26\">",
"       26",
"      </a>",
"      ]. Isolated thecal cells from ovulatory subjects with polycystic ovaries secreted as much 17-OHP and androgen in culture as did those from subjects who were hyperandrogenic and anovulatory [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/62\">",
"       62",
"      </a>",
"      ]. These observations are compatible with a restraining effect of normal granulosa cells in vivo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/63\">",
"       63",
"      </a>",
"      ] that is lacking in PCOS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum anti-M&uuml;llerian hormone (AMH) levels are increased in PCOS because of the increased number of small growing follicles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/64\">",
"     64",
"    </a>",
"    ]. AMH is a product of the granulosa cells within growing ovarian follicles and seems to regulate their growth and development by exerting a paracrine negative feedback effect on the recruitment of precursor (primordial) follicles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/63\">",
"     63",
"    </a>",
"    ]. The excessive folliculogenesis of PCOS arises because an increased proportion of follicles leave the resting (primordial) phase and begin growing. In PCOS, there appears to be resistance to the inhibitory effect of AMH on follicular recruitment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/63\">",
"     63",
"    </a>",
"    ]. The altered granulosa cell function seems in part to result from excessive androgen production by intrinsically defective theca cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/40\">",
"     40",
"    </a>",
"    ], although it may in part be independent of hyperandrogenism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oocyte gene expression is also dysregulated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/66\">",
"     66",
"    </a>",
"    ]. High quality oocytes have abnormal gene expression profiles that are associated with defective meiosis or early embryonic development. A high proportion of the differentially expressed genes contain androgen and peroxisome proliferator-activated receptors. This is compatible with excessive androgen and epigenetic metabolic signals contributing to the reduced developmental competency of PCOS oocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11771185\">",
"    <span class=\"h2\">",
"     Insulin resistant hyperinsulinism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin-resistant hyperinsulinism is an important extrinsic factor in the steroidogenic dysregulation of PCOS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/17\">",
"     17",
"    </a>",
"    ]. Ordinary PCOS appears to be a state in which tissue-selective insulin resistance is paradoxically associated with ovarian sensitivity to insulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Insulin resistance is common in PCOS (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/13/39130?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features and diagnosis of polycystic ovary syndrome in adolescents\", section on 'Manifestations of insulin resistance'",
"    </a>",
"    ). In addition, all extreme states of insulin-resistant hyperinsulinemia, such as hereditary cases that are caused by insulin receptor mutations or lipodystrophy, are accompanied by PCOS, suggesting a role for insulin in ovarian dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/36,67,68\">",
"     36,67,68",
"    </a>",
"    ]. These cases may be the result of extreme hyperinsulinemia excessively stimulating the insulin-like growth factor-I (IGF-I) signal transduction pathway in the ovarian thecal cell. This results in increased androgen production by blocking the normal cellular down-regulation of response to LH. The IGF-I excess state of acromegaly also is associated with PCOS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28567?source=see_link\">",
"     \"Insulin resistance: Definition and clinical spectrum\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More modest forms of insulin resistance also are associated with PCOS, including diabetes mellitus (DM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. As an example, premenopausal women with type 2 DM had a PCOS prevalence rate of 30 to 40 percent. In these patients, insulin levels are not sufficiently high to act via the IGF-I receptor and may be acting directly via the insulin receptor to stimulate androgen production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/72\">",
"     72",
"    </a>",
"    ]. Type 1 DM also is associated with PCOS; this association is thought to be due to the supra-physiologic systemic doses of insulin required to control glycemia in the absence of the efficient hepatic glucose utilization that normally results from insulin secretion into the portal system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between hyperandrogenism and insulin resistance appears to primarily result from the effect of the compensatory insulin excess on steroidogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/35,74\">",
"     35,74",
"    </a>",
"    ], although excess androgen has been reported to reduce insulin sensitivity in a minority of studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. Ovarian and adrenal steroidogenesis function as if they are sensitive to the hyperinsulinemic state, despite clinical evidence that overall glucose metabolism (which reflects primarily muscle metabolism) is resistant to insulin infusion. In the ovary, insulin acts in conjunction with LH to enhance androgen production and up-regulate LH binding (",
"    <a class=\"graphic graphic_figure graphicRef57364 \" href=\"mobipreview.htm?38/31/39423\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Defective whole-body glucose disposal in response to maximal insulin stimulation is related to defective skeletal muscle responsiveness of glucose uptake to maximal insulin stimulation. Both intrinsic defects in insulin signaling and factors in the in vivo environment contribute to insulin resistance in skeletal muscle. Abdominal adipocytes, however, are not intrinsically resistant to insulin: preadipocytes have no intrinsic defect in insulin signaling, and mature adipocytes have normal maximal glucose uptake in response to insulin, although they have impaired sensitivity to low-dose insulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/18,77\">",
"     18,77",
"    </a>",
"    ]. Notably, a common transcription factor, Kr&uuml;ppel-like factor 15 (KLF15), mediates insulin stimulation of both adipogenesis and testosterone formation. This observation has led to the proposal that increased KLF15 expression in response to the compensatory hyperinsulinemia of insulin resistance may mediate the obesity and hepatic steatosis of PCOS, while aggravating hyperandrogenism. Protein metabolism also remains sensitive to insulin in PCOS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/67,78,79\">",
"     67,78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypersensitivity to insulin arguably exists in lean women with PCOS who are not insulin-resistant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/19,79\">",
"     19,79",
"    </a>",
"    ]. In a study of nine lean women with PCOS and normal insulin levels, suppression of insulin was reported to reduce androgen and raise sex hormone-binding globulin (SHBG) levels, an effect that does not occur in normal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/12?source=see_link&amp;anchor=H11#H11\">",
"     \"Steroid hormone metabolism in polycystic ovary syndrome\", section on 'Role of insulin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Central adiposity has been thought to be important to the pathogenesis of the insulin resistance of PCOS, but this concept has been challenged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. For example, in a study of 31 PCOS and control subjects pair-matched for body mass index (BMI), waist circumference, hypertrophic adipocytes, and low adiponectin levels were significantly associated with insulin resistance determined by the euglycemic clamp method. However, abdominal or visceral fat volume according to a multi-slice magnetic resonance imaging protocol, macrophage density in fat depots, and androgen levels were not associated with insulin resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/81\">",
"     81",
"    </a>",
"    ]. The possibility that the relationship between central adiposity and insulin resistance is mediated by intrahepatic fat rather than visceral fat could not be excluded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/82\">",
"     82",
"    </a>",
"    ]. The low-grade inflammation of obesity, which increases in proportion to body mass regardless of PCOS status, contributes to insulin resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All treatments that lower insulin levels, including weight loss, improve excess ovarian androgen and ovulation. Insulin resistance also contributes to the pathogenesis of type 2 DM and the metabolic syndrome. Both are seen in patients with PCOS and lead to increased risk of future cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24297?source=see_link\">",
"     \"Treatment of polycystic ovary syndrome in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29479788\">",
"    <span class=\"h2\">",
"     A unifying model of PCOS pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our working model of PCOS pathogenesis is shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef87315 \" href=\"mobipreview.htm?38/46/39662\">",
"     figure 2",
"    </a>",
"    ). The essence of PCOS is functional ovarian hyperandrogenism. This can account for all the clinical features that characterize PCOS: hirsutism, anovulation, and polycystic ovaries. Tissue-specific insulin-resistant hyperinsulinism is found in about half of cases. This can both up-regulate androgen production in response to LH and stimulate adipogenesis.",
"   </p>",
"   <p>",
"    Secondarily, two vicious cycles of feed-forward effects occur. The modest hyperandrogenemia causes secondary LH elevation by interfering with estrogen-progestin negative feedback. In the presence of insulin excess, this LH excess aggravates the disorder. Insulin-resistant hyperinsulinemia also promotes adiposity, which in turn aggravates the insulin-resistant state.",
"   </p>",
"   <p>",
"    In most PCOS, the cause of ovarian hyperandrogenism seems to be intrinsic, and this seems to be the case for considerable insulin-resistance as well. In the absence of intrinsic ovarian dysfunction, hyperandrogenism of extra-ovarian origin is less likely to cause anovulation and polycystic ovaries.",
"   </p>",
"   <p>",
"    A number of inborn and environmental factors are known that can contribute to ovarian hyperandrogenism",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    insulin resistance. As discussed in the following section, polycystic ovaries, androgen levels, and insulin resistance are hereditary traits. Environmental factors include obesity and intrauterine androgen exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of polycystic ovary syndrome (PCOS) is unknown, but considerable evidence suggests that PCOS is a result of a complex trait that often first becomes apparent at the onset of puberty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/83\">",
"     83",
"    </a>",
"    ]. Heritable and nonheritable factors contribute to the phenotypic expression of PCOS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/13\">",
"     13",
"    </a>",
"    ]. The prevailing concept is that PCOS is the result of one of a number of intrinsic ovarian genetic traits that interact with one or more other congenital or environmental factors to cause dysregulation of steroidogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/84\">",
"     84",
"    </a>",
"    ]. This is essentially a \"two-hit model,\" that is, a minimum of two interactive factors is required for the disorder to become manifest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Heritable traits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twin studies suggest that genetic influences explain over 70 percent of PCOS pathogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/83,85\">",
"     83,85",
"    </a>",
"    ]. Heritable traits that have been identified as PCOS risk factors are:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Polycystic ovary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two studies suggest that the polycystic ovary of PCOS is inherited in an autosomal dominant fashion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Most PCOS adolescents with a polycystic ovary have either a mother with a polycystic ovary, which is usually asymptomatic, or a father with metabolic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A presumed second factor, in concert with the intrinsic genetic susceptibility defect in the ovary, would appear necessary to result in the clinical phenotype of PCOS (hyperandrogenemic anovulation) in the affected daughter, as suggested by the following observations:",
"   </p>",
"   <p>",
"    In a study of 214 sisters of 125 PCOS probands, defined by National Institutes of Health (NIH) criteria (80 percent) or Rotterdam criteria (20 percent), 70.5 percent had a polycystic ovary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/89\">",
"     89",
"    </a>",
"    ]. Of the sisters with a polycystic ovary, 25 percent had hyperandrogenic anovulation (ie, met NIH criteria for PCOS), 33 percent had oligomenorrhea or hirsutism (ie, met only Rotterdam criteria for PCOS), and 42 percent were asymptomatic. The group of sisters with a polycystic ovary resembled their proband sisters in both androgenic and glucose-metabolic traits, indicating significant heritability and cosegregation of these traits.",
"   </p>",
"   <p>",
"    Genetic studies have not taken into account the heterogeneity of steroidogenic function of the polycystic ovary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/31\">",
"     31",
"    </a>",
"    ]. Our studies of adolescent and adult females indicate that half of apparently normal females with a polycystic ovary have no biochemical evidence of ovarian androgenic dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/25\">",
"     25",
"    </a>",
"    ]. While such women have a significant moderate elevation of serum anti-M&uuml;llerian hormone (AMH), in the absence of hyperandrogenism this seems to indicate an increased ovarian reserve (an enlarged oocyte pool) that predicts a prolonged reproductive lifespan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, half of asymptomatic females with a polycystic ovary have evidence of ovarian androgenic dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/31\">",
"     31",
"    </a>",
"    ]. Our studies have shown that 43 percent of these women met Rotterdam criteria for PCOS (ie, they had baseline hyperandrogenemia in addition to their polycystic ovary) and had biochemical evidence of functional ovarian hyperandrogenism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/25\">",
"     25",
"    </a>",
"    ]. We have postulated that such women are at risk of PCOS. The other 57 percent had a \"dysregulated\" polycystic ovary: that is, although they were normo-androgenemic, they had PCOS-like 17-hydroxyprogesterone (17-OHP) hyper-responsiveness to ovarian function testing.",
"    <em>",
"    </em>",
"    We suspect that this latter group represents a PCOS carrier state. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/13/39130?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features and diagnosis of polycystic ovary syndrome in adolescents\", section on 'Ovarian findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Hyperandrogenemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-half of sisters of PCOS probands have an elevated serum testosterone level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/91\">",
"     91",
"    </a>",
"    ]. However, only one-half of these sisters with excess androgen had menstrual irregularity, and the other half remained asymptomatic. This suggests that these asymptomatic patients with excess androgen only become symptomatic in the presence of another precipitating factor(s).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Maternal PCOS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While PCOS has been identified in only a small fraction of mothers of adolescents with PCOS, maternal PCOS is a risk factor for PCOS in daughters. One study compared the singleton daughters of 99 women with PCOS (defined by NIH criteria) to those of 88 control women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/92\">",
"     92",
"    </a>",
"    ]; about two-thirds of the daughters were pubertal. A study in subsets of these groups showed the daughters of women with PCOS had higher AMH in infancy and early childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/93\">",
"     93",
"    </a>",
"    ]. At all pubertal stages, the daughters of women with PCOS had larger ovaries and higher insulin responses to the oral glucose tolerance test (OGTT) than the daughters of women without PCOS. Higher androgens and 17-OHP responses to gonadotropin-releasing hormone (GnRH) agonist testing emerged during the late stages of puberty. Half of the daughters of women with PCOS who were post-menarcheal had higher testosterone levels than any control daughters, which strongly suggests that these girls have PCOS, like their mothers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Metabolic syndrome (insulin resistance and obesity)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial factors related to metabolic syndrome (ie, insulin resistance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    obesity) in both parents, particularly the father, seem to be fundamental to the pathogenesis of PCOS. This was illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 35 families in the United States in which an adolescent girl had PCOS, 70 percent of the probands had a parent with metabolic syndrome; using ATP-III criteria for defining metabolic syndrome, 53 percent of fathers and 34 percent of mothers were affected [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/88\">",
"       88",
"      </a>",
"      ]. Using 2004 criteria for metabolic syndrome, that included glucose tolerance, 79 percent of fathers and 37 percent of mothers were affected. Excess adiposity was found in the majority of parents; 94 percent of fathers and 66 percent of mothers were obese or overweight. Abnormal glucose tolerance was present in 84 percent of fathers and 49 percent of mothers; half of these were diabetic (half occult) and half had impaired glucose tolerance (\"prediabetes\"). Notably, there was complete concordance between paternal metabolic syndrome and a polycystic ovary in their proband daughter.",
"     </li>",
"     <li>",
"      In a study that defined metabolic syndrome by ATP-III criteria and did not include glucose tolerance tests, fathers were confirmed to have an increased prevalence of excess adiposity (about 85 percent) and metabolic syndrome (42 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many attempts are being made to identify specific genes that underlie the proposed intrinsic ovarian traits that cause PCOS. Candidate genes that regulate the hypothalamic-pituitary-ovarian axis and those that are responsible for insulin resistance have been the focus of linkage and case-control studies. These studies have reported a wide array of candidate genes with linkage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    association with PCOS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/13\">",
"     13",
"    </a>",
"    ]. They include polymorphisms in genes encoding steroidogenic enzymes, sex hormone-binding globulin, cytochrome P450 subunits (site of steroidogenesis regulation), and the androgen receptor; polymorphisms at genetic loci associated with insulin sensitivity; and heterozygous mutations in the genes that cause congenital adrenal hyperplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/13,95-99\">",
"     13,95-99",
"    </a>",
"    ]. Linkages for polymorphisms in the fibrillin 3, proopiomelanocortin, and DENND1A (a regulator of Rab GTPases) genes have also been robust in many populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. Further work is needed to determine the roles of these gene products in the pathogenesis of PCOS. The task is complicated by the apparent heterogeneity of PCOS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40568?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology and pathogenesis of the polycystic ovary syndrome in adults\", section on 'Current perspective'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The puzzle of how the components of PCOS are interrelated remains to be solved. It is possible that the defects in steroidogenesis and metabolism share common determinants. For example, there is evidence that insulin action in steroidogenic tissue and adipose tissue involves a common mechanism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/52\">",
"     52",
"    </a>",
"    ]. This in turn raises the possibility that the mechanistic pathways underlying the diverse manifestations of PCOS may involve transcription factors common to both of these tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Intrauterine environment",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is becoming increasingly apparent that environmental insults during development induce persistent changes in the epigenome that lead to altered gene expression and adult disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/102\">",
"     102",
"    </a>",
"    ]. Intrauterine traits that have been studied as risk factors for PCOS are:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Congenital virilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCOS is common in females with congenital virilizing disorders, of which congenital adrenal hyperplasia (CAH) is the most frequent, but not exclusive, cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/83\">",
"     83",
"    </a>",
"    ]. Congenital androgenization has now been well-established to lead to PCOS features in several experimental animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/102\">",
"     102",
"    </a>",
"    ]. Studies in the rhesus monkey exposed to androgen excess early in gestation have been particularly informative, showing characteristic PCOS features. These animals have ovarian and adrenal hyperandrogenism, oligomenorrhea, polyfollicular ovaries, and elevated luteinizing hormone (LH) levels associated with resistance to negative feedback inhibition of LH release by progesterone. They also have abdominal obesity, insulin resistance, impaired glucose tolerance, and dyslipidemia.",
"   </p>",
"   <p>",
"    Mechanistic studies in the rat indicate that the neuroendocrine consequences of androgen involve suppression of estrogen induction of hypothalamic progesterone receptors; when androgen is given prenatally, this effect persists into adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/103\">",
"     103",
"    </a>",
"    ]. Studies in sheep indicate that prenatal virilization causes tissue-specific differential changes in genes that determine insulin sensitivity, with liver and muscle being insulin-resistant and adipose tissue being insulin-sensitive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Disturbed fetal nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence that adult insulin-resistant disorders can be programmed by the intrauterine environment and low birth weight is a marker for this \"metabolic programming.\" However, the relevance of this phenomenon to PCOS is debatable. A retrospective study evaluating Catalan girls with premature pubarche found that intrauterine growth restriction was associated with post-menarcheal PCOS and insulin resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/105\">",
"     105",
"    </a>",
"    ]. Similarly, a prospective historical evaluation for PCOS features and insulin resistance showed an association with low birth weight, irrespective of fetal undernutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/106\">",
"     106",
"    </a>",
"    ]. On the other hand, two studies of adults suggested that polycystic ovaries were significantly associated with both PCOS features and a relatively high birth weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. In contrast to all of these studies, larger longitudinal and retrospective studies in Northern Europe have found no relationship between birth weight and PCOS symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/109,110\">",
"     109,110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Postnatal environment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postnatal environmental risk factors for PCOS can be viewed as precipitating latent, congenitally programmed susceptibility traits to become manifest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Insulin-resistant hyperinsulinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;All insulin-resistant states are associated with PCOS. The compensatory hyperinsulinemia of insulin resistance is closely associated with the anovulation of PCOS. Ovulatory patients with PCOS are less insulin-resistant than anovulatory patients with PCOS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/111\">",
"     111",
"    </a>",
"    ]. Any treatment that lowers insulin levels improves ovarian dysfunction and ovulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/84,112-114\">",
"     84,112-114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ordinary obesity is the most common cause of insulin resistance, and we are in the midst of a worldwide obesity epidemic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/115\">",
"     115",
"    </a>",
"    ], which is one reason why PCOS may be recognized more in adolescence than in decades past. Weight loss sufficient to improve indexes of insulin sensitivity in patients with PCOS improves menstrual cyclicity and ovulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/116-118\">",
"     116-118",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24297?source=see_link\">",
"     \"Treatment of polycystic ovary syndrome in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two syndromes of intractable obesity in childhood, pseudo-Cushing's syndrome and pseudo-acromegaly, herald PCOS in adolescence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/119\">",
"     119",
"    </a>",
"    ]. These syndromes have hereditary roots in insulin resistance.",
"   </p>",
"   <p>",
"    The transient physiologic insulin resistance of puberty may contribute to anovulation and the development of PCOS during adolescence. Insulin resistance and compensatory hyperinsulinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/120-122\">",
"     120-122",
"    </a>",
"    ] normally peak in mid-puberty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33124614\">",
"    <span class=\"h3\">",
"     Hyperandrogenism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postnatal androgen excess causes ovarian hyperandrogenism in some animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/102\">",
"     102",
"    </a>",
"    ], as does androgen excess in girls with poorly controlled congenital adrenal virilizing disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/124\">",
"     124",
"    </a>",
"    ]. In some species, adipogenesis is also stimulated and glucose metabolism deteriorates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/102,125\">",
"     102,125",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Other precipitants and risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The LH excess of PCOS has been postulated to arise from a \"hyperpuberty\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/126\">",
"     126",
"    </a>",
"    ]. The best support for this theory is in the setting of congenital virilization, in which there is prenatal programming for LH excess at puberty (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Congenital virilization'",
"    </a>",
"    above.).",
"   </p>",
"   <p>",
"    Most uncontrolled follow-up studies of idiopathic sexual precocity have not been consistent with an increased incidence of PCOS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/127\">",
"     127",
"    </a>",
"    ]. However, a controlled study of girls with early puberty reported a higher prevalence of PCOS by Androgen Excess and PCOS Society (AES) criteria in 25 adolescents who chose treatment with GnRH agonist as compared with a similar group of 55 girls who declined treatment (36 percent versus 15 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/128\">",
"     128",
"    </a>",
"    ]. The treated group had significant elevation of androstenedione in association with menstrual dysfunction or polycystic ovaries. Confirmation in a randomized trial using highly specific androgen assays and a more firm PCOS diagnosis by NIH criteria is needed before considering GnRH agonist treatment to be a risk factor for PCOS.",
"   </p>",
"   <p>",
"    Premature adrenarche may pose a moderately increased risk for PCOS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/83\">",
"     83",
"    </a>",
"    ]. These individuals appear to carry a 15 to 20 percent risk of developing PCOS. These observations suggest that premature adrenarche may be an early manifestation of the steroidogenic dysregulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/62/21481?source=see_link\">",
"     \"Premature adrenarche\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adolescents appear particularly susceptible to develop PCOS when treated with valproic acid, an antiepileptic drug that augments the transcription of ovarian cytochrome P450c17 and other steroidogenic enzymes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/9/34970/abstract/129,130\">",
"     129,130",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23417457\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory symptoms and hyperandrogenism in women and can present during adolescence.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three sets of diagnostic criteria have been proposed for the diagnosis of PCOS in adults (",
"      <a class=\"graphic graphic_table graphicRef80095 \" href=\"mobipreview.htm?11/29/11740\">",
"       table 1",
"      </a>",
"      ). The most widely accepted set of criteria was developed at a National Institutes of Health (NIH) conference, and requires evidence of otherwise unexplained hyperandrogenism (eg, hirsutism, severe acne, male- or female-pattern alopecia, or biochemical evidence of hyperandrogenemia) and anovulatory symptoms (eg, menstrual irregularity) that are not explained by another disorder. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In adolescents, we suggest using the NIH criteria for the diagnosis of PCOS. The criteria proposed by the Androgen Excess and PCOS Society (AES), in which PCOS is alternatively defined as hyperandrogenism and a polycystic ovary, can be considered to represent a risk factor for PCOS in asymptomatic adolescents, or permits a provisional diagnosis of PCOS in adolescents symptomatic with hirsutism. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Adolescents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Determining whether menstrual patterns and ovarian morphology are normal or abnormal is more difficult in adolescents as compared with adults, and it requires special clinical and sonographic considerations. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Adolescents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PCOS is caused by excess production of androgens by the ovaries. The etiology is unclear. It is most likely a primary disorder of ovarian",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      adrenal steroidogenesis. In addition, PCOS is often accompanied by selective insulin resistance, in which muscle is insulin-resistant, while the ovaries, adrenals, and adipose tissue remain relatively sensitive to the effects of insulin, thereby promoting androgen production and obesity (",
"      <a class=\"graphic graphic_figure graphicRef87315 \" href=\"mobipreview.htm?38/46/39662\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H29479788\">",
"       'A unifying model of PCOS pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PCOS appears to be the result of a complex trait that usually first becomes apparent at the onset of puberty. It is probably the result of one or more ovarian genetic traits that interact with one or more other congenital or environmental factors to cause dysregulation of steroidogenesis. The most common postnatal environmental contributor is obesity. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/1\">",
"      Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004; 89:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/2\">",
"      Carmina E, Rosato F, Jann&igrave; A, et al. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 2006; 91:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/3\">",
"      Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89:2745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/4\">",
"      Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008; 93:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/5\">",
"      Fauser BC, Bouchard P. Uncertainty remains in women with PCOS regarding the increased incidence of cardiovascular disease later in life, despite the indisputable presence of multiple cardiovascular risk factors at a young age. J Clin Endocrinol Metab 2011; 96:3675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/6\">",
"      Stein, IF. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29:181.",
"     </a>",
"    </li>",
"    <li>",
"     Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In: Polycystic Ovary Syndrome, Dunaif A, Givens J, Haseltine F, Merriam G (Eds), Blackwell Scientific Publications, Cambridge 1992. p.377.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/8\">",
"      American Academy of Pediatrics Committee on Adolescence, American College of Obstetricians and Gynecologists Committee on Adolescent Health Care, Diaz A, et al. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Pediatrics 2006; 118:2245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/9\">",
"      Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/10\">",
"      Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/11\">",
"      Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med 2005; 353:2578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/12\">",
"      Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/13\">",
"      Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/14\">",
"      Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 2001; 16:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/15\">",
"      DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005; 83:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/16\">",
"      Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/17\">",
"      Rosenfield RL. Polycystic ovary syndrome and insulin-resistant hyperinsulinemia. J Am Acad Dermatol 2001; 45:S95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/18\">",
"      Ciaraldi TP, Aroda V, Mudaliar S, et al. Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J Clin Endocrinol Metab 2009; 94:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/19\">",
"      Baillargeon JP, Carpentier A. Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity. Fertil Steril 2007; 88:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/20\">",
"      Lewy VD, Danadian K, Witchel SF, Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr 2001; 138:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/21\">",
"      Rosenfield RL, Mortensen M, Wroblewski K, et al. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. Hum Reprod 2011; 26:3138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/22\">",
"      Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol 2010; 203:201.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/23\">",
"      Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003; 9:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/24\">",
"      Adams J, Franks S, Polson DW, et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 1985; 2:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/25\">",
"      Rosenfield RL, Wroblewski K, Padmanabhan V, et al. Antim&uuml;llerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril 2012; 98:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/26\">",
"      Mortensen M, Ehrmann DA, Littlejohn E, Rosenfield RL. Asymptomatic volunteers with a polycystic ovary are a functionally distinct but heterogeneous population. J Clin Endocrinol Metab 2009; 94:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/27\">",
"      Apter D, Vihko R. Serum pregnenolone, progesterone, 17-hydroxyprogesterone, testosterone and 5 alpha-dihydrotestosterone during female puberty. J Clin Endocrinol Metab 1977; 45:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/28\">",
"      Venturoli S, Porcu E, Fabbri R, et al. Menstrual irregularities in adolescents: hormonal pattern and ovarian morphology. Horm Res 1986; 24:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/29\">",
"      Venturoli S, Porcu E, Gammi L, et al. Different gonadotropin pulsatile fashions in anovulatory cycles of young girls indicate different maturational pathways in adolescence. J Clin Endocrinol Metab 1987; 65:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/30\">",
"      Codner E, Villarroel C, Eyzaguirre FC, et al. Polycystic ovarian morphology in postmenarchal adolescents. Fertil Steril 2011; 95:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/31\">",
"      Mortensen M, Rosenfield RL, Littlejohn E. Functional significance of polycystic-size ovaries in healthy adolescents. J Clin Endocrinol Metab 2006; 91:3786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/32\">",
"      Villarroel C, Merino PM, L&oacute;pez P, et al. Polycystic ovarian morphology in adolescents with regular menstrual cycles is associated with elevated anti-Mullerian hormone. Hum Reprod 2011; 26:2861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/33\">",
"      Venturoli S, Porcu E, Fabbri R, et al. Longitudinal change of sonographic ovarian aspects and endocrine parameters in irregular cycles of adolescence. Pediatr Res 1995; 38:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/34\">",
"      Taylor AE, McCourt B, Martin KA, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:2248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/35\">",
"      Rosenfield RL. Ovarian and adrenal function in polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999; 28:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/36\">",
"      Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 1995; 16:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/37\">",
"      Rosenfield RL, Bordini B. Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity. Brain Res 2010; 1364:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/38\">",
"      Brothers KJ, Wu S, DiVall SA, et al. Rescue of obesity-induced infertility in female mice due to a pituitary-specific knockout of the insulin receptor. Cell Metab 2010; 12:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/39\">",
"      Lawson MA, Jain S, Sun S, et al. Evidence for insulin suppression of baseline luteinizing hormone in women with polycystic ovarian syndrome and normal women. J Clin Endocrinol Metab 2008; 93:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/40\">",
"      Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 2004; 10:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/41\">",
"      Hirshfeld-Cytron J, Barnes RB, Ehrmann DA, et al. Characterization of functionally typical and atypical types of polycystic ovary syndrome. J Clin Endocrinol Metab 2009; 94:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/42\">",
"      McCartney CR, Bellows AB, Gingrich MB, et al. Exaggerated 17-hydroxyprogesterone response to intravenous infusions of recombinant human LH in women with polycystic ovary syndrome. Am J Physiol Endocrinol Metab 2004; 286:E902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/43\">",
"      Rosencrantz MA, Coffler MS, Haggan A, et al. Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2011; 96:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/44\">",
"      Carbunaru G, Prasad P, Scoccia B, et al. The hormonal phenotype of Nonclassic 3 beta-hydroxysteroid dehydrogenase (HSD3B) deficiency in hyperandrogenic females is associated with insulin-resistant polycystic ovary syndrome and is not a variant of inherited HSD3B2 deficiency. J Clin Endocrinol Metab 2004; 89:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/45\">",
"      Gambineri A, Vicennati V, Genghini S, et al. Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:2295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/46\">",
"      Nelson VL, Legro RS, Strauss JF 3rd, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 1999; 13:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/47\">",
"      Nelson VL, Qin KN, Rosenfield RL, et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001; 86:5925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/48\">",
"      Jakimiuk AJ, Weitsman SR, Navab A, Magoffin DA. Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries. J Clin Endocrinol Metab 2001; 86:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/49\">",
"      Ho CK, Wood JR, Stewart DR, et al. Increased transcription and increased messenger ribonucleic acid (mRNA) stability contribute to increased GATA6 mRNA abundance in polycystic ovary syndrome theca cells. J Clin Endocrinol Metab 2005; 90:6596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/50\">",
"      Gambineri A, Patton L, De Iasio R, et al. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/51\">",
"      Ehrhart-Bornstein M, Hinson JP, Bornstein SR, et al. Intraadrenal interactions in the regulation of adrenocortical steroidogenesis. Endocr Rev 1998; 19:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/52\">",
"      Du X, Rosenfield RL, Qin K. KLF15 Is a transcriptional regulator of the human 17beta-hydroxysteroid dehydrogenase type 5 gene. A potential link between regulation of testosterone production and fat stores in women. J Clin Endocrinol Metab 2009; 94:2594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/53\">",
"      Gonz&aacute;lez F. Inflammation in Polycystic Ovary Syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids 2012; 77:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/54\">",
"      Quinkler M, Sinha B, Tomlinson JW, et al. Androgen generation in adipose tissue in women with simple obesity--a site-specific role for 17beta-hydroxysteroid dehydrogenase type 5. J Endocrinol 2004; 183:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/55\">",
"      Vassiliadi DA, Barber TM, Hughes BA, et al. Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009; 94:3558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/56\">",
"      Jakimiuk AJ, Weitsman SR, Magoffin DA. 5alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1999; 84:2414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/57\">",
"      Mason HD, Willis DS, Beard RW, et al. Estradiol production by granulosa cells of normal and polycystic ovaries: relationship to menstrual cycle history and concentrations of gonadotropins and sex steroids in follicular fluid. J Clin Endocrinol Metab 1994; 79:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/58\">",
"      Coffler MS, Patel K, Dahan MH, et al. Evidence for abnormal granulosa cell responsiveness to follicle-stimulating hormone in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/59\">",
"      Anderson RA, Groome NP, Baird DT. Inhibin A and inhibin B in women with polycystic ovarian syndrome during treatment with FSH to induce mono-ovulation. Clin Endocrinol (Oxf) 1998; 48:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/60\">",
"      Winters SJ, Talbott E, Guzick DS, et al. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril 2000; 73:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/61\">",
"      Barnes RB, Namnoum AB, Rosenfield RL, Layman LC. The role of LH and FSH in ovarian androgen secretion and ovarian follicular development: clinical studies in a patient with isolated FSH deficiency and multicystic ovaries. Hum Reprod 2002; 17:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/62\">",
"      Gilling-Smith C, Willis DS, Beard RW, Franks S. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 1994; 79:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/63\">",
"      Carlsson IB, Scott JE, Visser JA, et al. Anti-M&uuml;llerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. Hum Reprod 2006; 21:2223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/64\">",
"      Webber LJ, Stubbs SA, Stark J, et al. Prolonged survival in culture of preantral follicles from polycystic ovaries. J Clin Endocrinol Metab 2007; 92:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/65\">",
"      Wang JG, Lobo RA. The complex relationship between hypothalamic amenorrhea and polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/66\">",
"      Wood JR, Dumesic DA, Abbott DH, Strauss JF 3rd. Molecular abnormalities in oocytes from women with polycystic ovary syndrome revealed by microarray analysis. J Clin Endocrinol Metab 2007; 92:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/67\">",
"      Flier JS, Moller DE, Moses AC, et al. Insulin-mediated pseudoacromegaly: clinical and biochemical characterization of a syndrome of selective insulin resistance. J Clin Endocrinol Metab 1993; 76:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/68\">",
"      Lungu AO, Zadeh ES, Goodling A, et al. Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2012; 97:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/69\">",
"      Kaltsas GA, Mukherjee JJ, Jenkins PJ, et al. Menstrual irregularity in women with acromegaly. J Clin Endocrinol Metab 1999; 84:2731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/70\">",
"      Peppard HR, Marfori J, Iuorno MJ, Nestler JE. Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care 2001; 24:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/71\">",
"      Conn JJ, Jacobs HS, Conway GS. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2000; 52:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/72\">",
"      Nestler JE, Jakubowicz DJ, de Vargas AF, et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998; 83:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/73\">",
"      Codner E, Escobar-Morreale HF. Clinical review: Hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 2007; 92:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/74\">",
"      Tosi F, Negri C, Perrone F, et al. Hyperinsulinemia amplifies GnRH agonist stimulated ovarian steroid secretion in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2012; 97:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/75\">",
"      Corbould A. Effects of androgens on insulin action in women: is androgen excess a component of female metabolic syndrome? Diabetes Metab Res Rev 2008; 24:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/76\">",
"      Cohen JC, Hickman R. Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. J Clin Endocrinol Metab 1987; 64:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/77\">",
"      Corbould A, Dunaif A. The adipose cell lineage is not intrinsically insulin resistant in polycystic ovary syndrome. Metabolism 2007; 56:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/78\">",
"      Book CB, Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1999; 84:3110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/79\">",
"      Poretsky L, Seto-Young D, Shrestha A, et al. Phosphatidyl-inositol-3 kinase-independent insulin action pathway(s) in the human ovary. J Clin Endocrinol Metab 2001; 86:3115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/80\">",
"      Barber TM, Golding SJ, Alvey C, et al. Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/81\">",
"      Manner&aring;s-Holm L, Leonhardt H, Kullberg J, et al. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab 2011; 96:E304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/82\">",
"      Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A 2009; 106:15430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/83\">",
"      Rosenfield RL. Clinical review: Identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/84\">",
"      Buggs C, Rosenfield RL. Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin North Am 2005; 34:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/85\">",
"      Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab 2006; 91:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/86\">",
"      Carey AH, Chan KL, Short F, et al. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. Clin Endocrinol (Oxf) 1993; 38:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/87\">",
"      Govind A, Obhrai MS, Clayton RN. Polycystic ovaries are inherited as an autosomal dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families. J Clin Endocrinol Metab 1999; 84:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/88\">",
"      Leibel NI, Baumann EE, Kocherginsky M, Rosenfield RL. Relationship of adolescent polycystic ovary syndrome to parental metabolic syndrome. J Clin Endocrinol Metab 2006; 91:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/89\">",
"      Franks S, Webber LJ, Goh M, et al. Ovarian morphology is a marker of heritable biochemical traits in sisters with polycystic ovaries. J Clin Endocrinol Metab 2008; 93:3396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/90\">",
"      Freeman EW, Sammel MD, Lin H, Gracia CR. Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women. J Clin Endocrinol Metab 2012; 97:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/91\">",
"      Legro RS, Driscoll D, Strauss JF 3rd, et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A 1998; 95:14956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/92\">",
"      Sir-Petermann T, Codner E, P&eacute;rez V, et al. Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009; 94:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/93\">",
"      Sir-Petermann T, Codner E, Maliqueo M, et al. Increased anti-M&uuml;llerian hormone serum concentrations in prepubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:3105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/94\">",
"      Coviello AD, Sam S, Legro RS, Dunaif A. High prevalence of metabolic syndrome in first-degree male relatives of women with polycystic ovary syndrome is related to high rates of obesity. J Clin Endocrinol Metab 2009; 94:4361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/95\">",
"      Urbanek M, Sam S, Legro RS, Dunaif A. Identification of a polycystic ovary syndrome susceptibility variant in fibrillin-3 and association with a metabolic phenotype. J Clin Endocrinol Metab 2007; 92:4191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/96\">",
"      Escobar-Morreale HF, Luque-Ram&iacute;rez M, San Mill&aacute;n JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 2005; 26:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/97\">",
"      Witchel SF, Lee PA, Suda-Hartman M, Hoffman EP. Hyperandrogenism and manifesting heterozygotes for 21-hydroxylase deficiency. Biochem Mol Med 1997; 62:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/98\">",
"      Li M, Youngren JF, Dunaif A, et al. Decreased insulin receptor (IR) autophosphorylation in fibroblasts from patients with PCOS: effects of serine kinase inhibitors and IR activators. J Clin Endocrinol Metab 2002; 87:4088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/99\">",
"      Serafini PC, Catalino J, Lobo RA. The effect of spironolactone on genital skin 5 alpha-reductase activity. J Steroid Biochem 1985; 23:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/100\">",
"      Ewens KG, Stewart DR, Ankener W, et al. Family-based analysis of candidate genes for polycystic ovary syndrome. J Clin Endocrinol Metab 2010; 95:2306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/101\">",
"      Welt CK, Styrkarsdottir U, Ehrmann DA, et al. Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry. J Clin Endocrinol Metab 2012; 97:E1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/102\">",
"      Padmanabhan V, Veiga-Lopez A. Developmental origin of reproductive and metabolic dysfunctions: androgenic versus estrogenic reprogramming. Semin Reprod Med 2011; 29:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/103\">",
"      Foecking EM, McDevitt MA, Acosta-Mart&iacute;nez M, et al. Neuroendocrine consequences of androgen excess in female rodents. Horm Behav 2008; 53:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/104\">",
"      Nada SE, Thompson RC, Padmanabhan V. Developmental programming: differential effects of prenatal testosterone excess on insulin target tissues. Endocrinology 2010; 151:5165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/105\">",
"      Ib&aacute;&ntilde;ez L, Potau N, Francois I, de Zegher F. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab 1998; 83:3558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/106\">",
"      Pandolfi C, Zugaro A, Lattanzio F, et al. Low birth weight and later development of insulin resistance and biochemical/clinical features of polycystic ovary syndrome. Metabolism 2008; 57:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/107\">",
"      Cresswell JL, Barker DJ, Osmond C, et al. Fetal growth, length of gestation, and polycystic ovaries in adult life. Lancet 1997; 350:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/108\">",
"      Michelmore K, Ong K, Mason S, et al. Clinical features in women with polycystic ovaries: relationships to insulin sensitivity, insulin gene VNTR and birth weight. Clin Endocrinol (Oxf) 2001; 55:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/109\">",
"      Laitinen, J, Taponen, S, Martikainen, H, et al. Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms. Int J Obes Relat Metab Disord 2001; 55:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/110\">",
"      Sadrzadeh S, Klip WA, Broekmans FJ, et al. Birth weight and age at menarche in patients with polycystic ovary syndrome or diminished ovarian reserve, in a retrospective cohort. Hum Reprod 2003; 18:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/111\">",
"      Franks S. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab 2006; 91:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/112\">",
"      Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 338:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/113\">",
"      Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003; :CD003053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/114\">",
"      Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/115\">",
"      James WP. WHO recognition of the global obesity epidemic. Int J Obes (Lond) 2008; 32 Suppl 7:S120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/116\">",
"      Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992; 36:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/117\">",
"      Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999; 84:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/118\">",
"      Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, et al. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 2005; 90:6364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/119\">",
"      Littlejohn EE, Weiss RE, Deplewski D, et al. Intractable early childhood obesity as the initial sign of insulin resistant hyperinsulinism and precursor of polycystic ovary syndrome. J Pediatr Endocrinol Metab 2007; 20:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/120\">",
"      Bloch CA, Clemons P, Sperling MA. Puberty decreases insulin sensitivity. J Pediatr 1987; 110:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/121\">",
"      Caprio, S, Jones, T, Tamborlane, W. Developmental changes in insulin action and secretion in childhood health and disease. Adv Endocrinol Metab 1994; 5:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/122\">",
"      Caprio S. Insulin: the other anabolic hormone of puberty. Acta Paediatr Suppl 1999; 88:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/123\">",
"      Moran A, Jacobs DR Jr, Steinberger J, et al. Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes 1999; 48:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/124\">",
"      Barnes RB, Rosenfield RL, Ehrmann DA, et al. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab 1994; 79:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/125\">",
"      van Houten EL, Kramer P, McLuskey A, et al. Reproductive and metabolic phenotype of a mouse model of PCOS. Endocrinology 2012; 153:2861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/126\">",
"      Nobels F, Dewailly D. Puberty and polycystic ovarian syndrome: the insulin/insulin-like growth factor I hypothesis. Fertil Steril 1992; 58:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/127\">",
"      Carel JC, Roger M, Ispas S, et al. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty. J Clin Endocrinol Metab 1999; 84:1973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/128\">",
"      Chiavaroli V, Liberati M, D'Antonio F, et al. GNRH analog therapy in girls with early puberty is associated with the achievement of predicted final height but also with increased risk of polycystic ovary syndrome. Eur J Endocrinol 2010; 163:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/129\">",
"      Nelson-DeGrave VL, Wickenheisser JK, Cockrell JE, et al. Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology 2004; 145:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/9/34970/abstract/130\">",
"      Herzog AG. Menstrual disorders in women with epilepsy. Neurology 2006; 66:S23.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5799 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6ED53622C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_9_34970=[""].join("\n");
var outline_f34_9_34970=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23417457\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - NIH criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Rotterdam criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - The Androgen Excess and PCOS Society (AES) criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Abnormal pituitary function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Abnormal steroidogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Functional ovarian hyperandrogenism (FOH)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Functional adrenal hyperandrogenism (FAH)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Intrinsic factors underlying dysregulated steroidogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H121492970\">",
"      - Extrinsic factors contributing to dysregulated steroidogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H121493091\">",
"      - Other organs contributing to dysregulated steroidogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H121493139\">",
"      - Granulosa cell dysfunction and increased folliculogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11771185\">",
"      Insulin resistant hyperinsulinism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29479788\">",
"      A unifying model of PCOS pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Heritable traits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Polycystic ovary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Hyperandrogenemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Maternal PCOS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Metabolic syndrome (insulin resistance and obesity)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Intrauterine environment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Congenital virilization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Disturbed fetal nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Postnatal environment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Insulin-resistant hyperinsulinemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33124614\">",
"      - Hyperandrogenism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Other precipitants and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23417457\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5799\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5799|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/31/39423\" title=\"figure 1\">",
"      Ovarian steroid biosynthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/46/39662\" title=\"figure 2\">",
"      PCOS pathogenesis model",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5799|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/29/11740\" title=\"table 1\">",
"      Dx criteria PCOS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/13/39130?source=related_link\">",
"      Clinical features and diagnosis of polycystic ovary syndrome in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/36/39495?source=related_link\">",
"      Diagnosis of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40568?source=related_link\">",
"      Epidemiology and pathogenesis of the polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28567?source=related_link\">",
"      Insulin resistance: Definition and clinical spectrum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/17/16660?source=related_link\">",
"      Pathogenesis of ovarian hyperstimulation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/62/21481?source=related_link\">",
"      Premature adrenarche",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/12?source=related_link\">",
"      Steroid hormone metabolism in polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24297?source=related_link\">",
"      Treatment of polycystic ovary syndrome in adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_9_34971="Classif uterine sarc GOG";
var content_f34_9_34971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of uterine sarcomas",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Nonepithelial tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Endometrial stromal tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Stromal nodule (benign)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Endometrial stromal sarcoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Undifferentiated endometrial sarcoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Smooth-muscle tumors of uncertain malignant potential",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Leiomyosarcoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Epithelioid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Myxoid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Mixed endometrial stromal and smooth-muscle tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Other soft-tissue tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Homologous",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Heterologous",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Mixed epithelial-nonepithelial tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Adenosarcoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Homologous",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Heterologous",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       With high-grade stromal overgrowth",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from the Gynecologic Oncology Group classification of uterine sarcoma.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_9_34971=[""].join("\n");
var outline_f34_9_34971=null;
var title_f34_9_34972="Minor congenital malformations A";
var content_f34_9_34972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Minor congenital malformations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Head and craniofacial structures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Skull",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abnormal hair whorls (absence, more than 2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Frontal bossing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Plagiocephaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flat occiput",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metopic fontanel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Eyes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epicanthal folds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypotelorism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypertelorism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Upslanting or downslanting palpebral fissures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Short palpebral fissures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Synophrys",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ptosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Ears",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ear lobe: attached, creases, notches, or bifid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Small ears",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lop ear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cup-shaped ear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Protruding ear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ear tags",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Preauricular sinuses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Nose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flat bridge",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anteverted nostrils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Philtrum long, short, flat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Mouth and jaw",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Microstomia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Macrostomia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bifid uvula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multiple frenula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Micrognathia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neck",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short neck",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Webbing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Redundant skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Branchial sinuses",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_9_34972=[""].join("\n");
var outline_f34_9_34972=null;
var title_f34_9_34973="Octreotide IFN met neuroend tum";
var content_f34_9_34973=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Efficacy of somatostatin analogs and interferon-alpha in advanced neuroendocrine tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent(s)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Patients N",
"       </td>",
"       <td class=\"subtitle1\">",
"        Biochemical response rate, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tumor response rate, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Author, year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Somatostatin analogs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"7\">",
"        Octreotide",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Kvols, L; 1986",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Kvols, L; 1987",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        Oberg, K; 1991",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Saltz, L; 1993",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        Janson, E; 1993",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Arnold, R; 1996",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        DiBartolomeo, M; 1996",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Lanreotide",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        Eriksson, B; 1997",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Ruszniewski, P; 1996",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lanreotide-SR",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Tomassetti, P; 1998",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Interferon-alpha",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"12\">",
"        IFN-alfa",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        Moertel, C; 1989",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        Hanssen, C; 1989",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Oberg, K; 1989",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Creutzfeldt, W; 1991",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        Oberg, K; 1991",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        Schober, C; 1992",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Joensuu, H; 1992",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        Biesma, B; 1992",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        Janson, E; 1992",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        Bajetta, E; 1993",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        DiBartolomeo, M; 1993",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Doberauer, C; 1987",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Somatostatin analogs plus interferon-alpha",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Uncontrolled series",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Janson, E; 1993",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        Frank, M; 1999",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Randomized studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lanreotide",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td rowspan=\"3\">",
"        Faiss, S; 2003",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        INF",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        3.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lanreotide + IFN-alfa",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        7.1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NR: Not reported.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_9_34973=[""].join("\n");
var outline_f34_9_34973=null;
var title_f34_9_34974="Changes in PD sodium ratio";
var content_f34_9_34974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F67695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F67695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Changes in peritoneal dialysis sodium dialysate/plasma ratio over time",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 431px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sodium D/P (dialysate/plasma) ratios versus time as measured in 1985 (5/23/85, white curve) and 1992 (7/06/92, black curve) in a patient with progressive loss of ultrafiltration. Values are superimposed upon the standard curves. The initial curve is normal, displaying an initial drop of the ratio; the second curve is abnormal with no decrease at the beginning of dwell. The curve rises steadily after a one hour dwell.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_9_34974=[""].join("\n");
var outline_f34_9_34974=null;
var title_f34_9_34975="Retrocuspid papilla";
var content_f34_9_34975=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retrocuspid papilla",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADtAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5h1B2F/cMAQPOYn0J3Go4pmEkaOxUK+fXHtXZ/ELw2LeafUtOjY2zuWmjX/lm2Tz/ALvX6Vw8TYmQtkjcCcdTzQBN5pFyWkfkP1IPvS/aZC6+ZyqkMAOoHtULcbiFAUse2cfh+Neg6J8Lda1Gxsb+9EVpa3R3LuOZQn97b0oA4yzW6u5kjgVpWY4VF6n29q9h8AfCHUNSj+06/L9mtx1SMjdn3Nd98MvA1nYhLezjgkkUHdPPhWbnnH+Fenyxy6ZveKK22D5So5I9PxoA4fS/Auk6JBt0ZbaaaMbmfq5H41pwRSNkEnYBkqvGBV+W2a45khWIynIK/ezViHTDbSr5z84BDr0B9CKAKVpbwt880cjIehUZqe9Wyt7VJAyuznBjYcg1WvbtrWcLGQCOpGMN6ZFYeo3rXMhldhvJy3YfQUAacd2kaFfvRtz2+Q1X/tAqpHOW4wPrxWMboowLgkegpjXTM4AbgjscUAX5bnhvLBDfWkaTcSSw54rP875SHOQTzx0oLruKlcjP3h2NAFgTbZMMOccE0GQLkqApHUdqqF8gKw4z1Bp0gfzWByTjnB60AXWcMN7EbeP/AK9PjlCHO3AA6ZrLbzNxwpZe+eo/+tU43HGc89KALsUpKNgnHTNCOWb5ScdT7VFFDM6BgpXOR0608RNhvKJB4BAFACSsFf5s844A6ip4Fd5dmCdzBVAHOacLdvsE0mRviwSrDBI6HFN06+IZCE+ZH3ZB7DFAEs0TwStG64b7vPf1qwsGEXzW2Z6Zqxe6jaz52KRcBy3zEYyf6VoWEC3Vv9umcOqt5YjUfdPbNAGasXlozOScHC9ifeo49Qjil2yuEzgFjzimazKyXsy3GWYnCgjHHrWPFE0zF522Ifu4GSfagDsv7QtUu3SeOWYSqrRtDyBn+L8PSqd1cQJ+6k2TSR8RyqcFfY/SseOTylVIyypnpnoabGWMrOerHqelAEs7OygZ3N2J61XmiJAJOD29PrShsSnLdfwBpHYsWHAB5Oe1ADAAwbkgg43Y61FNHlDgkEHoepqQuTkiQZPAJ6UyRmG0Fie2CeDQBTffHIAAu0D+LmnKf3J2HDA42561I2Wc5yMdjUTD5iR19fSgCCVmjlyBngj8KjMm2KRVBP58D2qxt85T1BxjPah1TBwcdAxNAFN9u37pIbmiNdwIBA75pPl3P5m7I656U0OE3Ac84FACyZ27sYyOOMVBtIQlhgKePerJCkngYYY5qnNwCu7avfA70ARXL/MCORjoD0qmXXywcsNpznFTS/PH1PPGf6iqs5zGip1PJGeaAKuoyAwsVORn14FW/AFwo0qZiOPOYAA+1ZN9gwyYGDjIX8KueA026RJlSxaVvwoA7RpBkBEIyMAZziiqsDbC5LcDB60VEqcZ/EgucndgCaXcu+MkggjgjJB+teZeJ/DMljfxtpytLa3EgWPaOUc/w/T0NekSzMcqOBuPfpzRptybW6hmWNZNsgJVhkcfyqwLfw6+ERSJdQ8RRi4uG+aO1PK/j6mvcNP0GO7a3WeNkjT5U3d8dvbFULDUZb+K0msVj8jbndydo9Dj0rq/Dl4ZrKfcvlz27/OFGAxoAJ7S00y3xDaRwNEARIepPf8AGqk88l6N53lWAYBv51keINdlnuSihWC4znkCk02/aYABQxGM9jQBoTxmKNJfMYY++xOfl9hU19qVumlbY5UkCKRkjLc9DiqM8zNBJN56IPunjJ/HNczql8JVaJSNucsR/HQBXurkMTklTnCkd6pzHcowf8aZ5oBKgYk7DHSq7SnflwQDwRigBxJzjIAJ4PvQ7Abefrx3qKWQBiMdv0qv5nzdWwefmoAvCTcBuPTjrT4STIQx56VRt1Zix34XtzitKwbzpfnUbscfX60AW4Y03ASLxjgetW1EEaMsg4254OMGqLyRwO4Tcxx1BwQfSoXuCUzjkc59aANKGdY5dgiDdcsecUoNvLdbnUGMAZQcFjWbbTETsCGxjjgVeHO4jg45I44oA1Y76OK2kRkzIG3IAent9KjRXGoRRxgSNJ8xKjOMj+lZSyJIGaNlLA4O3nmpru78uZJF38Jg4OKAL+pgDS4JJAisGZCc9R6mucbMJLHLKDxjoR9a1b+WCbRwrXIZy5dUC9e3NQW2l6vFbxG3RnSXDhVG4geuO1ADNMa0mmma5leL5cKcZ3fjS2GqT6bMWiJZGGGHY++KivNPvYt0s1tLEG5+ROB9aotu3sJGbJHU0AdVcW8txCJZBwBuyvTmqC5WQDABzzmpLE3B08SvIyvEVWHccBx3Wsya7Yu5YMhDfdJ/GgDTjgeaVvLIbGScileIwxeaGDMpBx1H40+2QQW8M13L5HmglQBkgeuB2qvOYEQyG9hJ6BUJyfwoAgMhx823GOh9ajL7jgg9eQOgqCWdSoXBOM8kdqi8xQTwSCeOM0AWmYOSScg+lP3KqHBJOcgdKpeaigYH44pJ7pMxkHp680AXLy6aZ2lmkLyE5OTyT61WwD/FyOvGKWCZRao1vhrkMWk3KCwHqop0erlLOZrhzctL8sfmAdfUj/CgCFuCqoynnoOx96fIyooKtyOT71Qmug7Mz7cnpgYqN5y23aMKMd/1oAsysgy6tklfToaqOwBUEsAOfr9KUu20q5wuOo71UM3JySwA5J9KALLyM+N2Qrdx2qObBLAcEZwfUVGz4U+WMgjpnNRHfsPmD3GD3oAZI+GkGOo6VSldsFsZJzk98/hVl1Ks4G7gjHcVA8rAb257c9Qf8KAMi/LbZGbcQQcc9K1vBqhNEifJBaRm45PXp71japL5dtMQAQQSFI747Yrc8MgpolvtI3Fc9e5oA03YCR255z1oqNkEKkuSQAcHvRSbYHMTSKZXztyxJ5OMGkjZWbcp+8eQO5qGTrIRkHPHPFPiKhvQnoRTA7PwP4jfSLiSCRmNtLwVJ79K9OXxhpVpprxWlnm6LHG5sqvuT3rwSGQAqyHa3PU+net7T70y2/mP90HBJPP5UAdndXUl3L5jBFA64PJq/osqxu7ENyMrz1PrXI21yPlJ3ezcVsWV2CCjMGXrkcUAbmqXoNqznbG78475/wD1VzLyANtB3K/zDtzVzUXKIq4I6DLLg4rKMhUgFSwORQBM7K2CCBn+dNZ/kAQKOe9RK6gLz+lR7sdDjryR+lAA5Xbk85HPtUDuwbBOccUrNhcg9ePTNRM53kH9BQBYgmVWZSvBGME9/rUkN06PlD97rxVJSDkjhV6dMU4MgPVs9cigDQt5wZv3iNIWOF5yc1qS2L+XHJIpVXJCAHJOPWufgmaJw8HyOpIycGuh+0wW8BmDebIOM7j8uRQA610+WXDDhQctz0q4LXYxibLTDkR9/r78VFY3MK2rSNJvmQriMnAOe+amfVlvGJQpHOCEQj175Pp70ARJaFpPKRGJx82BgD3q3fabMtqkjYIIB+U8EVDDcJbyNHNeB9wzuHt6etaL3sZu4YzJsSOIOsYGd/09zigDG03QzqevQ2CyAKRvkcdEXqfxr2AQ29vEkFqBFFEgVR14HqayPDOnRwXF5qIQZulQRhj8yjGT/hWsWwDuOAc0AZ1ywDYbHI5B6Gua1rQLO/bdEnlTFSSyLXVXKI2QuD6emaqk+XuJzuxgYHrQBwk2lfZrWC1uiV2E4uV5Bz2YdvrXNSjbIxLgRqxViec49PWvULtEJKrgqR36Vyer6BDcO5RmjlJ6Dp+VAHOXmoyXaRrJgCNBEoHBAqoV/ecsc+3ap5Lc6fdhdRjJhBzlD978e1Ou7pGG0WUaIPu4kyT7mgCH59oG7HuetPjLqM7lYZww6UXd1bmCIxr5ch6jOcH2qrFIZX2QJvdjgIO5oAkRwykktj09KZLtHG4FscAd67zQvA8X2ZZdXeRpSMiFeAo9z610WmaNpdjKn2a0j3Du/wAx/M0Aea6T4d1m/Ils7SQJjO9jtGPrVufwbq8SFsROw/hD/wCNev2rLFMX3YAOSOoNZmpTedI0yrtDHgDvQB4fdwzWsxjuIDE68HeP5etQswjZR03cZz1r1fU7G11CBorhQxB4OOR9DXnXiTw9PZs7W6NNBjKnGSPrQBno4ZHZSMHqCf51n3U/BUYVfei3gmldo7aKaSQnhVBJB9TUkukaqigvZTKBzjZnNABkvgq2Aw6DjNSiTCsrkhhjqegqsIZEcRSK0Tn+8CKhZ/LJUsobOTg/1oAsyusqsFBIYZP+fWqcoBdhH7dewpWlkBLSPtA/iFRTHcy4wQ2OfWgDK1UHyGRTxwCOMc101swtbCBEbcyKAfQcVzV3m6uoYNuC0g+nrW5fyNAojjwZWO0BRyc9qAIby9PlS7G3Ko+bJ4FFMtreW50hjHButpHKzDuTzg564orSElHcDKmlUnDLgMMDPGeetOjAWNQBgA5bnmq0h3D5mLY5G3pSs2wsrfNuHBArMCypyxABPquenvSpK8JjYvtHTOcfnVRG5O3gMeh9veq9w5azbcEL5OF6g/8A1qAOssrxhJHkbsEDGa6PSpo/NDNv2ZPC9vevPtFu3WCNmDAnjnv9K7XQke5t5J1HEZAIGP8AGgDf1tCYIpEEhAGdxPbtWKWHXc2MDAzXYC3t77SCCjCdCqgfwgZ+9/8Arrlr+JLeeRV+Zg3zEHjPpxQBCoycs3UE4K9KMMqg/NnP3RTVIypycYxmnO5JG09OeaAK8rEKV4yaQY5yCSPfihiS5AHB4+tIQAp3fe6kZoAYh3c7cnPK4wKeGO9jnA9xTGf5RjaBnmh2VVPXb3x60AKxw4K53dsVNDOQo3MeDnmoEwdzO3yjgU9VxKrIq5I644NAG1n5PNlUyiXblQORGD1JHTNVLoq0hWFgEXgDHv61Josoaf7NJlUkXbkdmHIzV3T9HErK92zrGxIjIGPMP9BmgDOgDea2cll9BnitvUiYINOkA2TmPO0ngDPBqlMEsGVTBKGznfv4PqBV37b/AGzrFhGYtirtiAz1GaAPXdHDrptt5h+bywWPoe9TSEkYHIzjApYWChQMgBcYpemd65U8MPU0AVpFDL6nGM+tZ91uJIP3QeK0pFBCkDjv7VSvUwhKLlR3J70AZcysGPKjt+FVpIWkfIPVhkjtWgiqykHAJ5z60xoQgZl3ADkAUAZ2txW13MYp4V8pUC4x19680v8ARXi1KRBKVhJwufT0r1C9EEi5cElh8pHXNYl9aRvfQp1Xds3kdKAOKGir0aSRsdK6v4ceFg2tfa3QssZ+XPr3NWP7NClhCQ+w4PHP1rtPDMS2ltD853nkkDpmgCfUWIuCedmelVlkTcPm5HoMcVoauFWQsMurchumaypk2nCj3z1oAtK2VBGTuGeafb6fPcQgyHyoQT85q1p1t9vmRuUjBCsvr71qX+CPs0TgEcnI4oA5S/0uMo5gdi+CQT61zUryK5Dqcr6jIrtLt1UEKML655NcxrUWLgSIOXGc+hoAhsmwf3apHhtzEKATW1IrlIxIWYSH5c+3WszT0SO0DNh5Gfp/dUf/AFzVjUJA9wmXOxVCsVPGaAMzVtHttVgnjnADJ/Fjn6g15L4k0efR7lg5MkDHKy+v1r2e2keWUwEj94cknqBSX1nZBJLclZ2z8zOo/SgD58muSGwT948Y7f41E92mCucE988V1fxI8PxaajajYIfJ6SRp/CexA9K4HTILrVNWhsIlDSSMOR2H/wBagDe0HTp9SnnktPlMYwsjKTz6f/XrTsvD0811jU5GieM/IYXwSfU5rttDsrXTAtlCoEaJgseSTU8lqPN3dfm5zzQBkXFpLDZGGzQsoTJOcHI4zRXQrb7osgZJBHNFcmInKLVo3+T/AEKSPBjKioSR2I5HTmnvMwydyjpjP0rKe92vtAzkZHPzZ/wpkl/kt5pK4Hy8+grrJNEymEHDZXqfTkelMlulKlOMnOcdqow3D3DOYY3feoB9h61o6fpt08vmSQSMMHHGA31NAFrSppRDaWrBXt0ZnRlPzAnqD+Veo6FeSaDok8N1pltOl4p2TMdzocdAa4jw1oUyLE90jBhzjHTNdk0ywRpGxDKhwsIxj6mgCXTtfu7eymhtsJHNgMmOg9jWexJCjv7VG2ZCThVyeQoxUbEpgAM0ePyoAmJBG7djA/GguccFR6H/AOvUalgyhPmOOgGeKu2+i6ldQyT21rI0Q7kYH4UAZwcBm55PXJzTSxYM4GWz/wDWpk7PHI8bxkSr94MKrJPtb92OetAFsSYAAIPP8Q6nvxQruWKgD69MGqjSZl4A6EgDnnNWM4O4r6kgGgCZd5GF4Xrj1oVw0jFQ24enOah3fOG6ED8BRGwMjFT1HDUAadmv76JS20MQu4+9a+oXs1q1vi5Yz20jxA/7P0rnrYSMBtJODnOenNaEt9bRqQIDNOTkyStkA+wHWgCZ769uVWFGZxn7m0Hn19q3fCUQfxRaLmIzxKWkKD5QR0/GuYaS4uwVT7nVgnAH5V2vw8VY5vKFuolCFnlJyz+g9hQB6dbyZY45wMVJyy/Jkt3qvbsqnjj29ae08YYGNslshgKAGFMFjyCBg5qrI4wY2AAI+WrUl4owNnt9BVWZ1cn5cMetAGZjEgz13D2qxcn5NwOc8DmoLsHfwMCm28rMzqw4AyCaAM/Udyqvmc88Y7VTify5EIj3sRwrflWvq5VyuzkADcSOAfSk02K4S8mMFuJCYtsZxkf/AK6AKOjrtkuFU4MkTpye+O/5Vp+HrhXsFXOMHafrWz4f0YWtu011sabl2Ab7vsa4/TdQWxvLqIoHSR8g+noaAOrldpYUQOSVGF47elJHbh5/KOAc9QelVjLu2PG3vwav2VxGsrSzLksuMe5oA1ciwsmERYMeM44PvVC3JcuzHI6dfWi4nluivOU6AAcAUrARlY8OqDnpxQBm6kwVm8sDdnAzVW4hRFJuohKWGVAPI9zV67hD3exshWycZzzVKeEyTlkZ9qdWPNAFBrVxARExCE527cke2azLiWVF2BSARz6Gt263IBEgPTcy55FUMqc5X2waAKumu5aVEQNI64U56UxQ3zv95V4OKLhEikHlEqw9DjFRvKqR7QcZHIBoAy9XRLq1mikXKMCGJ7isfwzoUNh9ovXRRKyYUhfuityTbcXCRnIXOSM/winuAbaMISA79MdABQBnR28qjzmIZmY5B4NXrZAzElstnqa11hSVV+UbQO3rUclpEHHG09SRQBJbLGsBZxkBTweQaKryrsjcRNnIII7iivBzepOM48kraeX6mtNHz/H4KSRA11cyZHTaMA+5q6nhTT4v+WW//aauuaMgc8ZGcmoZcBWJUc+vSveMipZWVlbRYS0V5Bxg8Ae9aMUysgESAKo+61VSu0sWG7I4xxx6VHG4B4yGzgbqALZmO4bmYDOMiowE3jaDkNjj+dN3ZILgbgcc023B89ETJJOFHrmgC3EvmyHywxd8AY5z9K6ey8JStJE19P5YYZKryR+NaenaBFpNrBPc4ku5FBA/551ofamwyljyDzntQBFpGnWulpIsSK7scFnAOR6VoG8PlGMfKgHAA4rLaTJwOMdPeo/MwSTnaO3vQBm+KNGi1RDLHhLpU4K/xexrzabfHIVnXYynkH6163vIA571w/j60WNo7tV+8dren1oA57zudynJPpwAKlWd8jevPYCs2GXLZGCQMZ9akMxLJk7cfwk0AXo3UnG7dnPGQPzpAerfdGR37VQhYuZBCpJzxgZxWhbWVzPJgqwUAct0oAswXOEKKzKh9B978Kv2+nTTlOBEuMn1NS6TpWwhyN0h/ib+ldBYsLZsyQrNx905GaAIbKwFuPLi3ZfnBPB+tdJ4ZUQXUjgk8YzjtWS84ml3IscGeF74FXrea406cMm3zSuQwOQynsRQB3CTNsGGXOOKRZvlOSdp46ViQzyizW5dVEQYLgH5iT6e1K2ows5Kq6qeRuNAG0GDK5yvBwAKQvJISqqT64GRWXDewHduYnOOM8VPJqCzOUgWQhuiRUASFhvxKRgnAzxg1WJiB4fg9ABnmoNQvZI3EclsIB1zJz+NZNzdM53eZgjkYGAKANK5mVFEXQse5yM+prbXxHYWViILbfI0XEjowUOT1Irg57h3HGVPcE9agDkphWOc9e1AHUap4okv7dIkhEEaggMrE7q51JAxzuBIP5monO2PI49+pquHK5zmgDqtLvVMaxOTx0JPWtUT4cYYEjoPWuKjn8tVMeOeo6mtOx1Ledj8bTwaAO20q6wXjdtp6jPQ1Yu5QS6s7Njnhuv+Ncokz7UfnDc5B9KnS/Yx4OPlPX0oA2HlBlWXaEUDJYg/lVe91FTD+7KKVU4AHJ+tZr3kuc5OT685/CqE044Lv2zjvQBea/CJ+8UPIQc468+tZZuGTIBy2eh7CoXmQMMbm+neqz3K4Y+WD25GaAJ5pyN+cMxOKo3FwRjB3Y4IqSdnKMxQFOw6Zqo9vMYl2jaScdaAIra7YXeQcZyPwPFdJ4egN+wkAysQwox71jW/g7XLyNpILRhGeS7fLke3vXbaDBcabZxW00LW0W75mC8+3NADzpMzSCNFHzdwOgrXi8M26Iq3cr+ZnkZ6ela9oRDAjQMsoJyWPGKkCSy3BLpktyCOaAMxfD1lFu8iEswBJc9j7UV0qBrSFjGcsRn5h0orxszoQqzi5v8A9K/Scf1NIOx8oSyHqDnjk1Wmm+Q5wBxwarm5DLlTk9selQTznGSBtPXnmvZMyx55ZgC1RrMzhQoUtk5PeqRmxuODkfrVq0iaWJckqpPB6ZoAlLZwyE4yAPrW74Zt0n1NZHLERfMc+tc3cRtbSZzuhJGCOoxXQeEpH893GSuMZJoA9I1KZriLcpOFGDWYJmJUDp34609ZQU27sBsD1qGc+WeCVxye4oAXf8jFgc9OKTey4IPyk9PWog38XGewprMV3FupPXrQBL5nHJwV6etY+txrd6fdRSFPmXKjPcdK1M8AA+p5qndDAUn5vegDxwTTy3ZihweSAVHeujstAcJG107MjjIUHOPqa1ntYEvZD5Kod3XofWte1VWgeJHGx8c4yaANLQtEsFjZfPAbaGO0Zz7VYltYROywxsEQfxdWP+FS211Da2a2sMAVDgyNnLOff2qtNdbp9wORjb74oAuw+XFEI44cuf4s1LcW8AnEZfMmwE46A+mazDMpUlcjHzA9KaJi6kYz33Z60ATvHuckkYHf1+lWrC+jgUK9oks68q7k4A9CO9ZofAye3fP86iM20kAA8DBNAHQXd9Ld5eZhvz9PyFRTH92dh684zVC2d5DGIwXkIwFxnNX/ALJOQfMwpA5X0/woAgErLIoY443VYg1K7hZjE7o2MHaccVGI9h+ZwWI9M1HJICXbtj/9dAE5uLm7uEMxZy3Qk5NTvbyBipCbsj+Lr7VkC8kjfK8EdK0YdTEkqi52bh0YcAfXFAEc9vcRBlkVwvY44qsFd8BE71p6dqe6edJGzHJkM3XA9hWlKLLTYoZIIXd2G4Mx70Ac2I3QYcHd1y3aodhIfkgDmt/U7kXEBZo2eWP5g6jsfWsDc2W9yOnagAVEXlmKnOM44qYEpICCpwOTUE/QbWyR29DUEUwi38nnsT0oA2IbmdB8u8qBk8VK17ICAh6HJFN0TWFs3ZWRZoW6kjFa0s63oaS3kXfjOxkAP4UAZqNO8jFuO5YngCobuFiCA2GwMnPBpsn2kSMXVxng+hqJ32Kqu/uQaAEY7R97oOTUayAt82QQM9egqvPLv3Ec/pUI3SgsowmCSfSgC4ZWeQCPLOeMZ/rXq/gnwpHBaxXmpRLJOy7lU8hf/r1xXw48NnVNTW6mQ/ZYeR6MRXtZUKgWPGAMKKAGnjbxhcflWfqEQkTe4BX07VpkAryCccEVXuACu3JAOQPegDEin6Kfl+bHHTFalipG4gHcOhbtTbDS44g/mgs5PftVwo0anYMkg89qACZkELeYN3y8nrRVOeZ/J5XAz83vRXj5nGo5R5Gl63/RGkD4k1Kb+zZAXJUAc57CkS8S4UkNkE/lVr4jWuLGWZARsAO7vivMoNRktG8sOSwIwUJr2DM9VhRZ1Cg7WyOtbsEe222yrjHTnp6VwPhnWo7koGfEoPfgGu2iuvNhyQCN2c556cUAWPk83y5QDG1OsCmm3rRJ92Qb1b+lMRgePk3kdfSpLiNZY0QjJByD6GgDrILmAWUbRZaRjls9jTLmbc25WJzx0rF064zD5Tsd3G5c4z7itKJ1eMYH5etAFhLgs7du1SykKoC5z3BPSqceRIGXP0HrUu/OQ2Tjj3oAXcQQSSRnGPSkYh0+ZD68cU5Tu+UgcclgeTSv8oIGcY4IoA5a6R2v4tpVFJxuP171oXFrJp8rco4/hkX7pPeq1/CWcjaVIOR/9anSb1YKQ4CjoTQBoRXhnwzIA3QkVI7g8KSGziqMcDuF559fSp7MwuzmWTZt6kjOaAJXOTlFy3YjtT1dQjYHTt/WonMbAFHJGcZpjK3YsXbgj2oAkMjMNzHGDgjHSom3PgBRuA5wegp4DKh2jjHUng0wgsjfe3D146UAdTZXlpbQ2Zsi32gIfM3eue34VYuJXd2AB8tjuzzzXKWUmyQHkE8VsyX0phIQHYF6gdKAJJ5MHIwc9M8VSlEjxswRto4OOmKheVgM55U5PPUUkWoSRZAOQBu2nkUAJcxGOPhuW6kVmybjnJO0nHy9qvS3ZlTBIODngdKpybmGB69c/wA6ANDSbkWsIuUj3+X8rBuRz0rRn1P7UuJY1Vid2R/IelZM9u1vbRINygruIz/OpSXe2EoVUij+XjvQBrPcxtbmKN3G5cNjnn0rLQ7Syn5h2GajiumhDYYHIwcjgVCWD7sdWxQBYMjEgjgZ4NRum52c8c9qrhxjdnPfGeaWKXa5+Y7T154oAeuUIPJP0pVvWyFLMT044pGdXAxkjHUioX4BZBznOR6UAa1jrM0Q5IIA5V+QBU9xPDfNIzBkA7jpXPCTAZtwwTnp1p8FyVYcnPofSgCadwkhUYBXqfWrOi6bPrWora2inBwGbPAHrVK0il1PUPKQfNu5x6V7T8PtJt9PtzIg+fuxHJNAHV+H9Lh0jS4bW2UYjADH+8e5q60gBPHI7jtSwplQc8ntTsemAOhoAN/yDA5/WmAc8gAe9TBAAMHr3prRgDPTp0oAYWOxup5wMUZ+8Dz049Kc45IPA7e1Mk7k42kcHvQBm6idsUj9CMmiqet3AjgZFIyBwaK87GxruS9k3/XzRcbdT5s8Q2C3Ng6HBBH9PSvn/WdOl0+8uImBC54OM5HYGvpq7gV1XHOQM8V5n8Q/DH2qJpolzKvIx6V6JB5PazywXaGJiAOOemMV6B4Y8RLcIom4Oe5rzuS28mVg330OCpXqcUWt1LarujPJbI54Hrx+VAHvNrKHZGU8E84rRTDn5h+RrynQfFLI6Rysu4kdeevbNej6dcx3MW5GXI6YHWgCxeEwukkeBnjPtWnY3HyqTgnqST0qjOrSRY4J7CqdvO0JVZDg9+aAOtBXy8DGeobrSIQFGeW9T2rLhu2KEEcDkkinidgMtjHqaANSNiucHIp80ny4J7dM1QjmJXjkdcVIGGRnBO6gBLmKMFc7hIOp9qgkXe2c5/2qnLLuPc5wfpUUjA8qBgY69RQA1JQu4FsHt6VWVsTNuHBPJpXYEgnpUEm9WGOFJ6CgDTjCPEFAGKcAACRzjggHrVWAsMckY7GrQKhjkkgj8zQAvmdAOnXpULNn6ccZ6mnM+DyCPcUwHgY6jmgAJbCgfQjpTo7yRJflIC9xnINKXBwpA46ioVAVuflGM0AaSy285yibH6gdqlS0tp1BjnEUxyDv+6KyFfBAyAcenpSGTIO9TwccHvQBcu7KezYhgp3DIIPGKbbBjJkjcMZAHNRozPHh3PpkVo6O8cE6vOfkbhto+YCgC9qSiW1iMa7N33Qw54Hc1U0+aKe0lt5QFc8nc3y/hVjXL9JQI4jiKPhCfSuencK27dx3zQAt2ggncRusiexqus2dxb7g4FU55HG4xkkZxUEdwXDZIXHUHrQBrRzDbntnikdzgkHIHbNZsTtvBB+XPerCyb1OD744oAnadgykFvl6jNNluTgLyPrUOeeoA9elRTuQMEA8dP8AGgCYypjJb/gPrUTTP5qqDz2x/Kq6yKoyOq4AI7VreFrP7dqZkOCsfJJGcmgDsfCemm1g3FcXL9SBzXsHh6OJLGEHqBz65rg9KjMW1WHzkZBNdhoVrczkOjlIjzyKAOljb5BkjLd/SpBx1Lc96zrmf7OuzfvcHGKf5rx2/nAgr6UAaO8KgA6DjinSE7eMVkx3ylRsIGex7VMLlDja6nHP0oAnZtqcE/nVO+ulijJJYDtk0S3CsnDEHOScYrmdbvvNcopLAe/NAFe8na6nITBA5BJ4oqPTwFl3ALhupaisqi1+Kw0ecSx71UL129B3+lUL6z8yN1lX5W+nNbCoNucndgdD04qKaLHKtwe1aiPEfHXhIrK13arhh8pAz065rzKe3kVV3owdmPOOCa+pdQshcxsroNp7Zryzxd4VKgvBEeTn5TgA+v1oA8oJaGQEZyMH6113hjxJcW0yQy58s4Ax/SsK5tiJ3SdGCgcOBgj2596pK4ikdRvIxj5ePxoA+g9Mv0urUMT8uOMGobm3LvlWyevAxXm3h7xPFYJHAz5RjkHOSB716NYaxaXgTymDjGAc8CgDQ02I72ErZAH4mnzuSxXBC464xzVmylWKbzmVSSOFPSoJ2BcsR8zZPFACb8YTv61LC7bgM8DoSazrmXYysvCjnij7ScAgkc45Oc0Aa7SgLwev61D5jtwWx3x3qhHNlz1H+e1TK/DfNznr3oAkL7SQRkY/OmAHduAIOQevFBZc7WOD1NKWXJyMECgC0hUDqWNTrICMAZ/lVEPkcEYHb+tPjkK89OO/pQBY80s3IyD/AAg8igsrDn5cH8KgZ22ADAyM4HrUJbuB39etAFneBkk/lTDIvO0HB/WoCwYDnk803dllKkYwe3U0AWPM4JJyefwpsb/ICACSenpUA74B7n3ApvRT5ZIzjmgC6s+AMAEKcYxVmGcxyBsqWx/FyPpWUsmHC5OM9OtD3BUMxYAKhPagDQkulYAN8xzgc8VQu7gZz94Z5ye9UDdmUAxsNrdMdcVTknOJEYnr25oAtXFzw+0LtHBPr3qmk/zSNgetRS3J2tuAGTgZrNW6YMRnv6Zz9KAN6K7ywCkYIx9atRuuDgEccnHNcz9tQBEfJOT2xirsd2F3FWLduT7UAbG4jb3yO9M81gCroGPZvWqEd7uB5J4p81yvygHAA65oAnC75lEZAY4HPf8ACvVPCGkLbW0cZAEhG5iB1rgfBWnNf6gty+fLjPGf4q9l0+MRQDC4OMCgDR02zFxcoGUEZx7V3UVtLHAscbBBxkgVjeGrAA+f1GM9K6mgDMGmopLOSzHkk96J4R5Zi3YB7Vov0qtcAlOOpNAHMavavaweZEc+tc4urTiUIOVyetdnfAmJkbO08iuKntBHdScYUnJoA1ZNRd7cbiMkce9ZIfzWwpPr0pXO7AQ4QdqfBG6YKBmK9BQBatVVRkA5zg45oq3Cp24bhu//ANaik79APOwm1cEAkjtSFMgFgVPTIrW8tWiAwMgA+lVFj2vyQO2aYFCeIBsjIIH+cVmXlmkisJMMT14xx7V0MkBYg45HQdaqPCjccFT3oA8b8Z+DvPLvAAHAyf8ACvLdY0mW0bLDbhRwe57ivqW+tlbIOCpFcf4g8NxXEEwESscEHK0AfPpO5FIXEsZ2nI5/GtLT9RuNNvGeNmGMct+ue2Km8TaW2l6lJACw8wfeJ4I96x3x9o4YAZOSueDQB6n4d8UiUKLg4k4zzjPuK6hrxJQpRgSf514haSyxLjBAGMknnr1rptM15otqTsZEP8QPegD0aWbPDZHpVWQuQWLd8EehrPsNQWZEOThhnJNWTKpyQeCenv60ATR3Dhh8xIz24rVhcBOGzkelZlnKrNymDz1/lUrTmMnHRTkDOc0AXxJuU8cgY6URsmBkcHr61QF0Txxk8Edz9Kf5pUYG09wp5oAveao6DqcHjpTHmbBBPHes+W4BkwuBjjHvUP2lwzFQSW5xjr/9agDWjm3KBn5wehNCTKY2x94HBNZkNx8pdlJfOBzUsZJ6/dGeehoAss52Anknpx3pQ+VJDDBPK46CqskpC7emRwx6AVC85Q5yuM/UUAaHmAICxYEds9KSSYCPaOR15qnDdLJDzl8HOBUBuFbCDIGc4PU/jQBekncgMWAA6kc/hUE0qvIQThSB26mqguVjDDgZJIqPzi4wQF70AErlc5IAXr9Kry7gxGB1yMH9adlmV/oOR1qNtjq2A2OgoAmdSYz3yfTgVXjhDOzSEADqAeR+FbGgCFbnN5hoVVuRnr2p5jtzIzDb83BBHf1oAwZLBGXcCyr1UOnUdO1VmhFu7N8/TB9enJrsF05ZI1ktt5bpjGRU1to95cMymJSX+XLDqKAOENyYsbHMhHGD2NdZ4V8OX/iKcPtaG24+Zup/DtXTaZ4DgeZJLtFIQ52jv7mvS9Igg0+38qKIAgYG0d6AI9B0K10u0SGONflHX3rrNH0yS7kXcMRL7dRS6HpLXIWWY4Xqors7eFbdAsaKoAoAlt4VhiVVUAAYGB0qWo1YDkknPPNOJPPfigBSfzqGdQVIP1pztgE4OeKrXEm0vle31yaAMvUpMAg9cc1y9yu5gv8Ae9OorW1a4yp4IOOorFgmX7SN5J9qAEFo6bcovI59MVoQopUblGV7D0qd7hCmO44PoartINhAHzGgAkYdPUYoqlczBCdxwOmaKTdgMO1wVKHGccc44qG4gViCcqoHftVJLnZLjDEdeDWkk6SqitjA+bHemBUkJxj5gcdB1qpIvIHQnqa0jHuJfP3TjPtUN4o2fKDu69M0AZLqquBn6+lVpoQ29SDtPXPerxT96vBoCHLHBOfXuKAOC8XeErfWYDuQeYvIYdq8l1vwnfabcsyp5kRy25RnB+lfSjwhyFOMA1RudPjc4YAgZGAKAPlo20yyEkBWBBIOeOOh/Wl2iOI4U5YbiV5HXHSvf9V8F2N2WZoRuP8AEBzXG6v8OnVQbRyGXjB5HWgDgrW/mtblT95QuCO3IrqtP1sSnBbY3o3f6Vm6j4V1SBjiHevbaD+ZrJlt54C7yxSKRwBs5LUAeh2N0JCWDLkev8qWa7Dddp2j9K4bTbi5MmwK7DoVA6VclvZllkicOjKRxjtQB07XClicHOM4FPM2RnJzjFcxaXzPJIJJN2OQcf0q+Z1YAjdgUAapuDjKsVI7HvRC4Rhl8EjIBrP+0kjK4JJ6gdzUrMR1ZiFHPI64oAuxTlsZ2hvXPercE7GIonLDnkismJ/Oj+Xhhknn2qW0Z45MSDaDxn0oA1ZXUxfORuHoeBWfI2E4IIPU98VLdttG0jK44Pc1SEmQQvXHUUAW4XwmVyRjj6dKrytk8Muc9c9KjtpPmO/O7sAP1FJdOY1ztGGOF7GgBzE4VmO4g8diKmhQBfmK8HGD1rKknkEeJBhi3UHoM08XxVQ8gyGOVyetAGmMDLY4JIA/xqq+FB647n/CoYXxvwSSBnHfrTZ5VVSI9rHBPXkUAbGjQyX13DaQsWeRiDkdB616/wCH/htYwRpJdMJJNuPm6H2rxrwrq4s9atrp4yEX5GI7D1r6W8N6ra3TQS+apQ9VJ/WgDPbQrG1G1YAh6ZYVU+xRrKxQYJ4x16V0/jGWEzJ9lIBIwQKydMt/NYGQ98n1oAhgjIGNnJ71oaPY/aLtQASi4yadf24t5QAWwegNdB4XgQRGQjOfzoA6GxgWONR/DjpV4jgYbp61FGB1Hp09BUu/kDn1oAAoH554FGNuSTxnNJuBbqwx2qJ5VGTk4HJJ7UAI5Y8HjtxWfqlysUXzOMngA9vem32pRxoSCFC9zXJ6lftcll52+9AFa9uHlmba26MHoagU7kIXgkjk8UhUKyjDYPUdaNuzLlm3EcZ6flQBcjbKgscY6VJLIVbIPHQGqaOMkEcHg47GnyM3ljuPc4oAjlJbI3Z57iiqUshBIGMZ/Oik4p7gc1do4wynqO3pSQXTIeD8oHQ9frV+SAMHABPAJ5rKulZCSC3A9OtMDegmMw5wMipihDDbwSMAd8ViaVcbAd3c4roUxIqkP8w9KAMqaJwxOxuTUA+ZhjcccYrdeDKhurEdDWdNaPGzMVyooAr8DPy/UCkI3n5Vxj0qUo2/69B3qUqME8biPzoAqtHgAqQBniojbK45HP061cSMrgFs49RQSOAuCRQBmyWMUhyij8RWbeaFBNlXgU5bjK810aqQvy7SabtPXng5JNAHGf8ACK2kLboYAhPHy9DWHrvgpNQckMVkyOVFeoeXkKqjjP402S2Vg3ODnHtQB4NdeB9UtGLQYmA69mxWDdW97YHy7q3aIbgQT3r6NlsiXAU8euetUL3Q4rhttxGj/WgDwSO+QnIIU5A56k+v611fhjQdQ15ibeMNGSQGPtXV3nw7sp2do4zFuPY4r1/4aaBb6PYxoEUlBjPU0AeW/wDCqtYjgMiHOf8AZ61g6t4S1jTyRPaMyjkELX1zE8e3bwF68dKhu7K3uoyJUU8dKAPjF7S42FRbysOn3DVEwSxMMRsNp5XZ1r7Ii8KaW3/LrFzzmqN74H0u4ZmEEe71x2oA+QWtrjeZRC4AxgAHmke1vLnZ/o8pIPde9fUtz4At0c+XFwfyqE+Bmj+ZVXPsKAPmWXS7pFRTazM2M5VenHrUEelXu1Q0Tbc9CORX03/whtw6nMa8dAKxdT0GSxwGgXBOMgUAeCw6HqErybYnwwxkrjvWpZeDJvNDzRuvbcGxmvWTZDyidgBz6U+O1Y8MBjOcUAcBY+FEi6lc12PheyFhOW3NtBztrQjsVU5yTnpircULRJ8iljjmgDS1GQTSRyIAQo55q3o9yi3o80qAMZIrMUFlDNwCegPSoZ48ZwcCgDq9bkt5iGhcMV6etX/DF1iNo9wBA79zXExlzj5ivpxmtO0vWt3LFSCehFAHpkExJ+Y9uSOtTNJgEhsYHFchpetLKypITjON3Tmtm81GOKMeW2SRkYPagC9Ndqitk546VgatrJGVjO5sdu9ZGoapJKdsZYD0z0ql80rNuYnI4560APmupZyzEnPZar4zjqWB6VIsZ2MQxPYe3vT2BAU9cdD6UAV5RjO3Aboailct/ECAMZ71Nc7WjUjg5yfQVQYYLHJAxkDrigC6koOMA5A71Xefdhzu645HWoBIVZdpIHQimlgSAW/GgBskiuPlYhhwc0VWldvPCIOB8+fQelFJq4EwcJGFxlj1OKyrtSxyOBk4962JIiHGDgYyPf61XuUCqwICk80wOdilaJieCoPHoTXVaPcqU+ZhvHrXNzQMc4OBzRaTvDcKOcA8j+tAHfworyBmAA6cVZ1CCJoSIlHoPesGx1PICt0Aq6t00rkSHIPSgDFeAxuXIyAfxoRWJbqB0rozDFJDlSvPtVR4Bhx97Ocn0oAxyjZKnOPSkCE42nBHUnqa1vsW5gQwy3SlayOSFHT2z+NAGZFGxOTnJ7GpVtWbJByOla0MBXcABnFTJagjqPw9aAMqO2YqB0x7cmp1tM8BQc1qiDpj71TLbZDAA5zgkcCgDFFhkg4HB9KYbFMHI75zjit7yMHaCOB0pphJG1V68D60AYIslUdOeOvNa1rcyQAIMA47VZ+ynOAOcYqUWnznCkAjHNAD49ScooZ+wqdNWJ6nODziqv2EhRkZ6ioHtdrcfj70AbcGrAcMwDHt7Vbi1KPdjua4+WF0y2Bz/KmxzyJnBP49BQB3aXKuyqD/APXqyHGemQK4iDUmVwxJ9MelasGqA4UlgcdzQB0gdRkY3Vja9ax3Fo5AXPWnJepIp+cZPTFUtRvAIGXjgHBBoA4ea2EUrqSxzyPc1AzFwBkA9z0zU89yJLxgSSORx2FaWk2sEsoEhGeuTQBQt7fyxuYZ749a1tPjiu2AKYUNg1euorSJf3Y5HbvUOmKB84AH9KAJ9S062hRQgGfrXPXMKIeeQeADzxWnqOpK3yqMuBgc1kF2kzwDyOo/lQAqSxR5wOT2x+VPllOBx83XJoism4JAPGPrUrQFSPkGDyPegCGOTLNuJ3Y4Aq0ZWZf4sdwf8aIbc5AkKg/Tk1ZjgLEZyR0AoAqBtpOM5brxzUy7SBgg8dTVk242cgdefpUUke11IGOvWgBS6gHacDsfU0yYqynBznt0FNztQcYUnIpsh3E5655NAEMxXAyRjPWqE4AzzyDxVqdC2AARgdu59arStvUHADY5PSgCv5nGxiVxxx39Kbu+VQeT9aGJwvGTRHHukU4IyehFACjdnBycjn060VfSPaQuMryOeKKQBwmA56jPP8qzLuQFjuPH86t3LFXQHnIPXtVK7UfM3dRTAikRWiYjA/2sfpWLIrNIeO+0YHWtvywQqnJGM9e9KYF3dvXgUAUbMyYXBIGcZ7Vu2wffvyT79vpTba3VDGwxgHpitS3hGGwcDOMYoAchIUAnaRzxzk1MsZ5AIII5zU0KDYV9DU2VJACgZPNAECQNuOVHA59KtiBgOB83Q+1Tqg5B5GcVIijHPOT/ACoArLCSPnX8QP0qRbdlbLAVbBO0jsTjB7CrKDaD34AH5UAUltnCnO3AwTUq25YfXqOlXM43YA5WpVYs65x8n60AZ8lsV42rgn05oS237Typ7e9aSNl/MIGcYxSpwQB0TkfjQBS+ygLkjHPGeeacYQu7p7mrshG7gDioxtLY2/dOaAK3lAIQzYz1PemvCJBlAD+lW929XJHUjimPIVk4AAOBgUAZMttyQc5x09aqzWewEkru/lW47DzGO0ZP6VBKoYNkD5T270Ac69oBGSPlHvVcrIueoIGa33jBLvnkjH0qpcgCKTCgbRigDMhvHjIycEn6Uy6vw1vluoOARTp0RZWYDnbjrWXcnCLnnANAFAli24kc9M9qv2l3LEwB6E4x6VFAiybcj7tXntkBXBINACTXMjbi6tnHzHPWoYLuf0I3cA1ZWBWGTn6Voabbp5uAOF7HmgDLitJ7ltxHBbBrfsNKOfnA5GAPeteytYUMeEBGS2K1YFSMkqoxu6UAc9NYFQTg4z970NQm23fKFBIBxn1rp51R40BX7z9vrVORApGRuG7gelAGIlk23eVHIqwtsyqPlq47BYiCMkDrTJLgxxKMZwoPJoAoy/uyTkKDz/8AWqjMwYhT1PQDk1buXZwWzjK5OO/eqE4GUK5BJz1oAjbGSmRvxggmoXXBOQAF9+tPd8xD5RnOSe5qCZjsOcEFgQPSgBJZCchQCP4qpz42kdWJ7dqmmcgMw6nAP50AgsTjntn6UAVHjLAFRx3x0qxHGEBYLnaM8/1q7ZQrKnOB1OMcVXvUAjkI4GRwPpQBUMrDnAznj86KaApKrjqRzRQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A retrocuspid papilla in a 7-year-old child. Note the firm, round papule on the attached gingiva lingual to the mandibular canine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Delaney JE, Keels MA. Pediatric oral pathology. Soft tissue and periodontal conditions. Pediatr Clin North Am 2000; 47:1125. Copyright &copy; 2000 WB Saunders.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_9_34975=[""].join("\n");
var outline_f34_9_34975=null;
